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Summary 
 
The growth controlling mammalian Target of Rapamycin (mTOR) is a conserved 
Ser/Thr kinase found in two structurally and functionally distinct complexes, mTORC1 
and mTORC2.  The tumor suppressor TSC1-TSC2 complex inhibits mTORC1 by 
acting on the small GTPase Rheb, but the role of TSC1-TSC2 and Rheb in the 
regulation of mTORC2 is unclear.  Here we examined the role of TSC1-TSC2 in the 
regulation of mTORC2 in human embryonic kidney 293 cells. Induced knockdown of 
TSC1 and TSC2 (TSC1/2) stimulated mTORC2-dependent actin cytoskeleton 
organization and Paxillin phosphorylation.  Furthermore, TSC1/2 siRNA increased 
mTORC2-dependent Ser473 phosphorylation of plasma membrane bound, 
myristoylated Akt/PKB.  This suggests that loss of Akt/PKB Ser473 phosphorylation 
in TSC mutant cells, as reported previously, is due to inhibition of Akt/PKB 
localization rather than inhibition of mTORC2 activity.   Amino acids and 
overexpression of Rheb failed to stimulate mTORC2 signaling.   Thus, TSC1-TSC2 
also inhibits mTORC2, but possibly independently of Rheb.  Our results suggest that 
mTORC2 hyperactivation may contribute to the pathophysiology of diseases such as 
cancer and Tuberous Sclerosis Complex. 
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I.  Introduction 
 
 
I.1  Growth 
 
Cell growth, the increase in size due to accumulation of mass, is a fundamental 
process for eukaryotic life (Thomas and Hall, 1997).  Environmental and genetic 
determinants, such as nutrients, growth factors and their according sensory signaling 
pathways control cell growth.  The limiting factors for cell growth are amino acids 
(Dann and Thomas, 2006) and energy, which depends on glucose metabolism and 
mitochondria (Hardie et al., 2006).  A major nutrient sensor in eukaryotes is the 
serine/threonine kinase target of rapamycin (TOR). Single-cell eukaryotes like the 
yeast Saccharomyces cerevisiae depend on environmental nutrients as their major 
stimulating source for growth. Metazoans distribute nutrients throughout the organism 
and specify cell growth via diffusible growth factors.  Only the cells that express and 
present compatible receptors sense growth factors.  Upon growth factor binding, the 
receptor triggers intracellular signaling cascades that induce growth.  In higher 
eukaryotes like flies and mammals, signaling from growth factors converges with 
signaling from nutrients and energy in the TOR signaling pathway, indicating an 
evolutionary extension of the functionally conserved TOR signaling pathway (Jacinto 
and Hall, 2003; Martin and Hall, 2005).  Remarkable examples for the importance of 
TOR signaling in biology include the contribution to human diseases such as cancer 
or tuberous sclerosis complex (TSC) (Petroulakis et al., 2006) and the embryonic 
lethality of tor deficient mice (Gangloff et al., 2004). 
 
 
I.2  TOR 
 
TOR was originally identified in yeast as the cellular target of the bacterial macrolide 
rapamycin (Heitman et al., 1991).  Since then it was found in many eukaryotes 
including fungi, plants, worms, flies and mammals (Jacinto and Hall, 2003).  Yeast 
has two distinct TOR genes, TOR1 and TOR2, whereas all other eukaryotes 
investigated so far have only one TOR. 
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TOR is a typical phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) that 
exclusively phosphorylates proteins on serine or threonine residues (Abraham, 
2004).  TOR proteins are highly conserved and consist of N-terminal HEAT repeat 
stretches (huntingtin, elongation factor 3, A subunit of protein phosphatase 2A 
(PP2A), and TOR1) (Andrade and Bork, 1995).  These stretches are followed by a 
FAT domain (FRAP, ATM, TTRAP) (Bosotti et al., 2000) that is located next to the 
FRB (FKBP12-rapamycin binding) domain (Lorenz and Heitman, 1995).  The FRB 
domain is neighbouring the catalytic domain, which is located close to the C-terminal 
FATC domain.  
 
HEAT repeats are predicted to form α-helical structures. The HEAT repeats in 
TOR mediate multimerization (Takahara et al., 2006), interaction with other proteins 
(Kim et al., 2002; Wullschleger et al., 2005) and membrane localization of yeast 
TOR2 (Kunz et al., 2000).  The FAT and FATC domains, which flank the FRB domain 
and the catalytic domain, are present in all PIKK family members.  Based on 
structural resolution, the FATC domain in TOR forms an α-helix with a C-terminal 
disulfide bond between two cysteine residues that is sensitive to the cellular redox 
state and mediates TOR protein stability (Dames et al., 2005).  Inhibition of TOR by 
rapamycin occurs via binding of the FKBP12-rapamycin complex to the bundle of 
four-α-helices in TOR that are formed by the FRB domain (Leone et al., 2006).  
Apparently, the FRB domain interacts with the catalytic domain in TOR and together 
these two TOR domains mediate yeast caffeine-sensitivity (Reinke et al., 2006).  The 
catalytic domain in TOR is highly homologous to the catalytic domains in PI3-kinases 
but unlike those, the TOR kinase does not phosphorylate lipids, which is the major 
criterion for TOR’s affiliation to the PIKK family (Abraham, 2004).  A repressor 
domain has been identified in mammalian TOR (mTOR) between amino acids 2430 
to 2450 as its deletion increases mTOR activity (Edinger and Thompson, 2004; 
Sekulic et al., 2000).  Two proximal phosphorylation sites are located in this domain, 
Thr2446 and Ser2448. Thr2446 is phosphorylated by the AMP-dependent kinase 
(AMPK) (Cheng et al., 2004) and Ser2448 is phosphorylated by S6K1 (Chiang and 
Abraham, 2005; Holz and Blenis, 2005).  It is unknown whether phosphorylation of 
mTOR on these two sites has physiological consequences.  In addition, mTOR 
autophosphorylates on Ser2481 but also for this site the physiological relevance is 
not determined (Peterson et al., 2000).  
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I.3  TOR complexes 
 
TOR controls a wide range of cellular processes, of which some are rapamycin-
sensitive and others are rapamycin-insensitive.  Whether a TOR signal is rapamycin-
sensitive or not depends on the two structurally distinct protein hetero-complexes in 
which TOR is signaling, the rapamycin-sensitive TOR complex 1 (TORC1) and the 
rapamycin-insensitive TOR complex 2 (TORC2) (Loewith et al., 2002).  Both TOR 
complexes, like TOR itself, are structurally and functionally conserved in eukaryotes 
including fungi, plants (so far only TORC1), worms (so far only TORC1), flies and 
mammals (Wullschleger et al., 2005).  TOR complexes form active homo-multimers 
in yeast, flies and mammals (Takahara et al., 2006; Wullschleger et al., 2005; Zhang 
et al., 2006b). 
 
 
I.3.1  TORC1 
 
Yeast TORC1 consists of either TOR1 or TOR2, KOG1 (kontroller of growth), LST8 
(lethal with sec thirteen) and TCO89 (Loewith et al., 2002; Reinke et al., 2004).  
TCO89 is the only non-essential component of TORC1 in yeast.  Drosophila TORC1 
(dTORC1) contains dTOR (Oldham et al., 2000; Zhang et al., 2000), dRaptor (Hara 
et al., 2002; Sarbassov et al., 2005b) and dLST8 (Yang et al., 2006).  In mammalian 
TORC1 (mTORC1), mTOR (Brown et al., 1994; Chiu et al., 1994; Sabatini et al., 
1994) associates with raptor (regulatory associated protein of mTOR; KOG1 
ortholog) (Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002) and mLST8 (Kim 
et al., 2003; Loewith et al., 2002). So far, no ortholog was found for TCO89 in 
mTORC1.   
 
Raptor consists of a highly conserved N-terminal domain of unknown function 
that locates next to three HEAT repeats, which are followed by seven WD-40 
repeats.  WD-40 repeats form propeller-like structures that mediate protein/protein 
interactions (Pickles et al., 2002).  Multiple sites in raptor are needed for its 
interaction with the HEAT repeats in mTOR (Kim et al., 2002).  It was reported that 
the mTOR/raptor interaction is regulated by nutrients and mLST8 (Kim et al., 2002; 
Kim et al., 2003), but a different report could not reproduce the nutrient sensitivity of 
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the mTOR/raptor interaction (Oshiro et al., 2004).  In yeast, nutrients do not affect the 
interaction between TOR and KOG1 (Loewith et al., 2002).  The FKBP12-rapamycin 
complex binds TOR exclusively in TORC1 (Loewith et al., 2002).  The inhibitory effect 
of rapamycin on mTOR signaling towards raptor-dependent substrates results from 
the interference of the FKBP12-rapamycin complex with the mTOR/raptor association 
(Kim et al., 2002; Oshiro et al., 2004).  LST8 consists of seven WD-40 repeats and 
binds to the catalytic domain of TOR in both complexes, TORC1 and TORC2.  In 
both of these complexes LST8 mediates integrity and is essential for TOR kinase 
activity (Kim et al., 2003; Loewith et al., 2002; Wullschleger et al., 2005). 
 
 
I.3.2  TORC2 
 
TORC2 in yeast contains TOR2, AVO1 (adheres voraciously to TOR2), AVO2, 
AVO3, LST8, and BIT61 (Loewith et al., 2002; Reinke et al., 2004).  AVO2 and BIT61 
are the only non-essential components of TORC2 in yeast.  In Dictyostelium 
discoideum, TORC2 (Dd-TORC2) consists of  Dd-TOR, RIP3 (AVO1 ortholog), 
Pianissimo (AVO3 ortholog) and Dd-LST8 (Lee et al., 2005b).  Drosophila TORC2 
(dTORC2) is formed by dTOR, dSIN1 (AVO1 ortholog) (Frias et al., 2006), dRictor 
(AVO3 ortholog) (Sarbassov et al., 2005b) and dLST8.  Mammalian TORC2 
(mTORC2) consists of mTOR, SIN1 (AVO1 ortholog) (Frias et al., 2006; Jacinto et 
al., 2006), rictor (rapamycin-insensitive companion of mTOR; AVO3 ortholog) and 
mLST8 (Jacinto et al., 2004; Sarbassov et al., 2004).  So far, no orthologs were 
found for AVO2 and BIT61 in mTORC2.  SIN1 and rictor bind cooperatively to mTOR 
in mTORC2 (Frias et al., 2006; Jacinto et al., 2006), similar to the cooperative binding 
of AVO1 and AVO3 in yeast TORC2 (Wullschleger et al., 2005).  AVO1 and AVO3 
bind multiple sites in TOR2, of which some are located in the HEAT repeats of TOR2. 
Functional domains in SIN1 and rictor have not been identified.  Knockout of either 
SIN1 or rictor in mice results in embryonic lethality (Jacinto et al., 2006; Shiota et al., 
2006). 
 
Although rapamycin does not inhibit TORC2 because the FKBP12-rapamycin 
complex cannot bind to TORC2, recent work claimed that prolonged rapamycin 
treatment can inhibit mTORC2 assembly and thereby abrogate mTORC2 signaling 
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(Sarbassov et al., 2006).  As rapamycin could inhibit mTORC2 assembly only in 
some but not in all tested cell types, the physiological effects of long-term rapamycin 
treatment await further characterization. 
 
 
I.4  TOR functions 
 
TOR controls cell growth by regulating transcription, translation, metabolism, survival 
and the cytoskeleton.  
 
 
I.4.1  TORC1 functions in yeast 
 
In yeast, TORC1 controls translation initiation by repressing GCN2 from inhibiting the 
eukaryotic initiation factor eIF2α (Cherkasova and Hinnebusch, 2003), and by 
repressing the eIF4E associated protein EAP1 (Matsuo et al., 2005).  As a 
consequence from translational control,  TORC1 affects G1-phase progression 
during the cell cycle (Thomas and Hall, 1997).  TORC1 controls nutrient- and stress-
responsive transcription in yeast by regulating localization of several transcription 
factors such as GLN3, MSN2, MSN4 and RTG1-RTG3 (Jacinto and Hall, 2003).  In 
concert with PKA, TORC1 controls yeast ribosome biogenesis by acting on 
transcriptional regulators like the transcription factors RRN3 and FHL1, and the 
histone deacetylase RPD3 (Martin and Hall, 2005).  Type 2A protein phosphatases 
(PP2As), which dephosphorylate NPR1 and GLN3 in yeast, are controlled by TORC1 
via regulation of the phosphatase repressor TAP42 and its regulator TIP41 (Jacinto 
and Hall, 2003).  Nutrient uptake in yeast is also controlled by TORC1 via regulation 
of the tryptophan permease TAT2 (Beck et al., 1999) and the glucose transporter 
HXT1 (Schmelzle et al., 2004).  TORC1 in yeast controls autophagy and glycogen 
accumulation via signaling crosstalk with the PKA pathway (Schmelzle et al., 2004).  
TORC1 inhibits yeast autophagy also via phosphorylation of ATG13, which is a co-
activator for the autophagy inducing kinase ATG1 (Miron and Sonenberg, 2001).  
Inhibition of TORC1 increases life span in yeast (Powers et al., 2006). 
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I.4.2  TORC2 functions in yeast 
 
Yeast TORC2 controls cell polarity by activating the RHO1 and RHO2 GDP/GTP 
exchange factor (GEF) ROM2 to regulate actin cytoskeleton organization (Schmidt et 
al., 1997).  Signals from RHO towards the yeast actin cytoskeleton are transduced 
via the RHO effector PKC1 (Helliwell et al., 1998).  In addition, TORC2 signaling 
maintains yeast viability via direct phosphorylation of the substrates YPK2 (Kamada 
et al., 2005) and the functionally redundant proteins SLM1 and SLM2 (Audhya et al., 
2004).  SLM1 and SLM2 mediate TORC2 inhibition towards calcineurin-dependent 
gene transcription (Mulet et al., 2006).  
 
 
I.4.3  TORC2 functions in Dictyostelium 
 
In Dictyostelium, Dd-TORC2 controls cell polarity, chemotaxis, activation of adenylyl 
cyclase and Akt/PKB phosphorylation (Lee et al., 2005b) (see I.4.7 and I.5.3 for 
further details on Akt/PKB phosphorylation). 
 
 
I.4.4  TORC1 functions in Drosophila 
 
In Drosophila melanogaster, dTOR controls larval development, cell growth and 
overall body size, which is mediated at least partially via regulation of Drosophila S6 
Kinase (dS6K) (Montagne et al., 1999; Oldham et al., 2000; Zhang et al., 2000). Like 
in mammals, dS6K hyperactivation by dTORC1 exerts negative feedback signaling 
towards Chico, the Drosophila IRS homolog, to inhibit insulin stimulation of 
Drosophila protein kinase B (dAkt) (Yang et al., 2006) (see I.4.6 and I.5.2 for further 
details on IRS-1 regulation).  dTORC1 controls translation initiation by regulating 
dS6K and d4E-BP (eIF4E-binding protein) (Miron et al., 2003; Miron and Sonenberg, 
2001; Radimerski et al., 2002; Sarbassov et al., 2004).  Like in yeast, dTORC1 
affects cell cycle progression (Bjorklund et al., 2006).  Furthermore, dTORC1 affects 
the timing of neuronal differentiation (Bateman and McNeill, 2004).  In the Drosophila 
fat body, dTOR controls a nutrient-sensitive humoral growth mechanism towards 
peripheral tissue (Colombani et al., 2003), lipid vesicle aggregation (Zhang et al., 
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2000) and autophagy (Rusten et al., 2004; Scott et al., 2004).  dTORC1 controls 
autophagy and protein degradation also via inhibition of the clathrin uncoating 
ATPase Hsc70-4 that mediates a late step in endocytosis (Hennig et al., 2006).  
dTORC1 activates transcription of genes that are regulated by a hypoxia inducible 
factor (HIF) responsive element (HRE) (Dekanty et al., 2005).  In fruit flies, like in 
yeast and worms, inhibition of dTORC1 mediates life span extension (Kapahi and 
Zid, 2004; Martin and Hall, 2005).  
 
 
I.4.5  TORC2 functions in Drosophila 
 
Similar to mTORC2 signaling, dTORC2 controls activation of dAkt through direct 
phosphorylation of the hydrophobic motif in dAkt (Sarbassov et al., 2005b) (see I.4.7 
and I.5.3 for further details on Akt/PKB phosphorylation). 
 
 
I.4.6  TORC1 functions in mammals 
 
In mammals, mTORC1 controls cell growth predominantly by stimulating the 
translational machinery and thus, protein synthesis (see Figure I-1).  Translation 
initiation is activated by mTORC1 via phosphorylation of 4E-BP (eIF4E-binding 
protein) (Hay and Sonenberg, 2004).  mTORC1 also stimulates translation by 
phosphorylating S6 kinase (S6K) (Ruvinsky and Meyuhas, 2006).  Translation is 
further activated by mTORC1-controlled ribosome biogenesis, which occurs via S6K-
regulated translation of ribosomal proteins and transcription of ribosomal RNA (rRNA) 
(Mayer and Grummt, 2006).  Like in Drosophila and yeast, mTORC1 affects cell cycle 
progression (Fingar and Blenis, 2004).   
 
Learning and memory are enhanced by mTORC1 (Bekinschtein et al., 2006; 
Dash et al., 2006; Tischmeyer et al., 2003) via regulation of long-term potentiation 
(LTP) (Cammalleri et al., 2003; Tang et al., 2002) and long-term depression (LTD) 
(Hou and Klann, 2004) at post-synapses of neuronal dendrites in the hippocampus 
and the cerebral cortex.  LTP and LTD drive synaptic plasticity and are regulated via 
inhibition of 4E-BP, which contributes locally to the translational competence of 
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certain stored mRNAs (Banko et al., 2006; Gong et al., 2006).  mTORC1 maintains 
LTP upon stimulation by Brain-Derived Neurotrophic Factor (BDNF) (Hay and 
Sonenberg, 2004) and upon activation of glutamatergic receptors (Lenz and Avruch, 
2005).  Changes of dendritic spine and soma morphology in hippocampal neurons, 
resulting from deficiency in the tuberous sclerosis complex genes TSC1 and TSC2, 
are mediated by mTORC1 hyperactivation (Tavazoie et al., 2005).  Furthermore, 
mTORC1 signaling in the hypothalamus reduces food intake (Cota et al., 2006).   
 
mTORC1 controls insulin-sensitivity via an S6K-dependent negative feedback 
loop towards insulin receptor substrate-1 (IRS-1) (Harrington et al., 2005) that limits 
glucose uptake in skeletal muscle, adipocytes and liver cells during prolonged insulin 
stimulation (Tremblay et al., 2005).  Adipogenesis is supported by mTORC1 via 
enhancement of rapamycin-sensitive PPARγ (peroxisome proliferator-activated 
receptor) nuclear receptor activity (Kim and Chen, 2004) and via insulin- and amino 
acid-stimulated phosphorylation of lipin (Huffman et al., 2002).  mTORC1 controls 
transcription by promoting expression and stability of the transcription factor HIF-1 
(hypoxia-inducible factor 1), which increases glucose uptake and glycolysis by raising 
expression of the glucose transporter GLUT1 (Hudson et al., 2002) and glycolytic 
enzymes during hypoxia (Nakamura et al., 2005).  By regulating HIF-1, hyperactive 
mTORC1 also induces neovascularisation in cancer cells due to increased 
expression of VEGF (vascular endothelial growth factor) (Brugarolas et al., 2003; 
Nakamura et al., 2006).  Transcription is further regulated by mTORC1 via 
phosphorylation of the transcription factor STAT3 (signal transducer and activator of 
transcription) (Yokogami et al., 2000).  Via STAT3 phosphorylation, mTORC1 
controls rapamycin-sensitive survival of neural stem cells (Androutsellis-Theotokis et 
al., 2006).  mTOR, most likely in mTORC1, controls clathrin mediated endocytosis 
that is required for transferrin internalization and thus, iron uptake (Pelkmans et al., 
2005).  mTORC1 suppresses autophagy in nutrient rich conditions (Meijer and 
Codogno, 2006). 
Since mTORC1 also inhibits the phosphatase PP2A (Peterson et al., 1999) and 
activates PP5 (Huang et al., 2004) it is important to consider that mTORC1 regulates 
not only phosphorylation of downstream targets but also dephosphorylation (Gingras 
et al., 2001b). 
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Some of the developmental defects observed in tor-/- knockout mice rely on impaired 
mTORC1 signaling, as can be seen in the trophoblast growth defect that appears 
after rapamycin treatment (Martin and Sutherland, 2001). 
 
 
 
I.4.7  TORC2 functions in mammals 
 
In mammals, mTORC2 controls actin cytoskeleton organization but the regulatory 
mechanism is still unclear and might differ between cell types (see Figure I-1).  In 
HeLa cells, it has been claimed that mTORC2 signals to actin via activating PKCα 
(Protein Kinase C) to prevent stress fiber formation and alter Paxillin localization 
(Sarbassov et al., 2004).  In NIH3T3 fibroblasts, it was found that mTORC2 is 
required for Paxillin tyrosine phosphorylation (Tyr118) and activation of the small 
GTPases Rac and Rho (Jacinto et al., 2004).  Paxillin is an adaptor for many proteins 
and is involved in the regulation of cell shape and motility (Brown and Turner, 2004).  
Paxillin, like mTORC2, has a fundamental function in mammalian growth and 
development as illustrated by the embryonic lethality of paxillin-/- knockout mice 
(Hagel et al., 2002).  Adhesion or stimulation with either growth factors or phorbol 
esters induces Paxillin Tyr118 phosphorylation by FAK (focal adhesion kinase) or Src 
(Sarcoma causing protein).  Lamellipodia formation and cell motility depend on 
Paxillin Tyr118 phosphorylation.  Paxillin Tyr118 phosphorylation recruits DOCK180, 
a GEF for Rac1, to activate Rac1.  Rac1 activation induces lamellipodia formation 
(Nobes and Hall, 1995).     
 
mTORC2 activates Akt/PKB (product of the retrovirus AKT8/Protein Kinase B) 
by directly phosphorylating Ser473 in the hydrophobic motif of Akt/PKB (Sarbassov et 
al., 2005b).  mTORC2-dependent regulation of Akt/PKB is needed for Akt/PKB-
dependent inhibition of the Forkhead box O transcription factors (FoxO) (Jacinto et 
al., 2006).  Although Akt/PKB is an upstream activator of mTORC1, mTORC2 does 
not regulate mTORC1 signaling (see also I.5.3) (Jacinto et al., 2006; Jacinto et al., 
2004; Sarbassov et al., 2004). 
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I.5  mTOR effectors  
 
mTOR regulates many important steps in growth control by directly phosphorylating 
4E-BP1, S6K and Akt/PKB (see Figure I-1). 
 
 
 
I.5.1  4E-BP  
 
4E-BP1 (eIF4E-binding protein) represses translation initiation via inhibitory binding 
to eIF4E (eukaryotic initiation factor 4E) .  mTOR-dependent phosphorylation of 4E-
BP1 on Thr37, Thr46, Ser65 and Thr70 inhibits 4E-BP1 by decreasing its affinity to 
eIF4E and releases eIF4E (Burnett et al., 1998; Gingras et al., 2001a; Mothe-Satney 
et al., 2000b).  The rapamycin-sensitive phosphorylation sites Thr37, Thr46, Ser65 
and Thr70 in 4E-BP1 share a Ser/Thr-Pro motif and are hierarchically regulated by 
mTOR (Brunn et al., 1997; Gingras et al., 1999; Mothe-Satney et al., 2000a).  mTOR 
potentially phosphorylates all rapamycin-sensitive sites in  4E-BP1 directly (Brunn et 
al., 1997; Mothe-Satney et al., 2000a).  However, due to differences in rapamycin-
sensitivity and in-vitro phosphorylation between the sites Ser65/Thr70 and 
Thr37/Thr46, it has been proposed that mTOR would directly phosphorylate 
Thr37/Thr46 but regulate phosphorylation of Ser65 and Thr70 in 4E-BP1 via an 
indirect mechanism (Gingras et al., 2001b).  Upon release from 4E-BP1, eIF4E binds 
to one of the scaffold proteins eIF4GI or eIF4GII, which additionally recruits the RNA 
helicase eIF4A to form the protein complex referred to as eIF4F.  eIF4F binds the 7-
methylguanosine triphosphate capped 5’-end of mRNA and eIF4A together with the 
co-factor eIF4B melts RNA secondary structures.  The ribosome-associated factor 
eIF3 then tethers the 40S ribosomal subunit to eIF4G.  The 5’- and 3’-termini of the 
mRNA are brought into proximity through the interaction of the poly (A)-binding 
protein with eIF4G, which increases the rate of re-initiation.  The small ribosomal 
subunit together with a ternary complex composed of eIF2, GTP, and the initiating 
Met-tRNAi (methionine transfer RNA) are then scanning the mRNA from 5’ to 3’ for 
an AUG start codon.  At the start codon, the initiation factors are released, the large 
60S ribosomal subunit is recruited, and translation elongation continues (Gingras et 
al., 2001b; Raught et al., 2000; Wang and Proud, 2006).  
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4E-BP1 is regulated by mTORC1 (Hara et al., 2002) and even mTOR-dependent in-
vitro phosphorylation of 4E-BP1 that is bound to eIF4E is sensitive to the FKBP12-
rapamycin complex (Wang et al., 2005).  A conserved TOR signaling (TOS) motif in 
4E-BP1 mediates interaction of 4E-BP1 with the mTORC1-specific component raptor, 
which is crucial for mTOR-dependent phosphorylation of 4E-BP1 (Choi et al., 2003; 
Nojima et al., 2003; Schalm et al., 2003).  The conserved TOS motif (with the amino 
acid sequence: FEMDI) is located in the C-terminus of 4E-BP and corresponds in 
function and sequence to a TOS motif in the N-terminus of S6K (Schalm and Blenis, 
2002).  Another conserved sequence in the N-terminus of 4E-BP1 is the RAIP motif 
(termed according to its amino acid sequence) (Tee and Proud, 2002).  Although the 
function of the RAIP motif is controversially debated, this motif is required for 
phosphorylation of specific mTOR-dependent sites in 4E-BP1 (Beugnet et al., 2003; 
Choi et al., 2003; Eguchi et al., 2006). 
 
4e-bp1-/- knockout mice do not develop a dramatic phenotype other than a 
reduction in white adipose tissue.  This mild phenotype may be due to the redundant 
roles of the expressed 4E-BP1 homologs 4E-BP2 and 4E-BP3 (Tsukiyama-Kohara et 
al., 2001).  The physiological relevance of a tight control of translation initiation is 
reflected by the oncogenic potential of the eIF4F subunits and the tumor suppressing 
effects of 4E-BP1 (Petroulakis et al., 2006). 
 
 
I.5.2  S6K  
 
S6K1 belongs to the AGC family of serine/threonine protein kinases (Protein Kinases 
A, G and C) (Belham et al., 1999; Peterson and Schreiber, 1999) and has two 
mammalian isoforms out of a single gene, p70S6K1 and p85S6K1.  Both isoforms 
are similarly regulated and differ in their N-terminus by a nuclear localization signal 
(NLS) that is only present in p85S6K1 (Dufner and Thomas, 1999).  Mammals have a 
second S6K gene S6K2, a close homolog of S6K1, which is highly conserved in 
sequence, function and regulation (Martin et al., 2001).  S6K1 activation requires 
phosphorylation in its activation loop on Thr229 by the phosphoinositide-dependent 
kinase PDK1 (Alessi et al., 1998).  Thr229 phosphorylation depends on prior 
rapamycin-sensitive phosphorylation of the hydrophobic motif in S6K1 on Thr389 by 
   - 12 -
mTORC1 (Ali and Sabatini, 2005; Hara et al., 2002; Kim et al., 2002; Pullen et al., 
1998).  Phosphorylation on Thr389 allows S6K1 to interact with PDK1 (Saitoh et al., 
2002). mTOR also phosphorylates the rapamycin-sensitive Ser371 in S6K1 that is 
required for S6K activation (Saitoh et al., 2002).  Furthermore, mTOR phosphorylates 
the Ser/Thr-Pro sites Ser411, Thr421 and Ser421 (Isotani et al., 1999) in the S6K1 
autoinhibitory domain to increase S6K1 catalytic activity (Dufner and Thomas, 1999).  
The TOS motif in the N-terminus of S6K1 (amino acid sequence: FDIDL), analogous 
to the TOS motif in 4E-BP1, mediates interaction of S6K1 with raptor and is crucial 
for mTOR-dependent phosphorylation of S6K1 (Nojima et al., 2003; Schalm and 
Blenis, 2002).  In S6K1, the TOS motif suppresses the inhibitory effect of a short 
domain in the C-terminus towards the catalytic domain (Schalm et al., 2005). 
 
S6K1 had been suspected to specifically increase translation of 5’-TOP 
(terminal oligopyrimidine tract) mRNA by phosphorylating the 40S ribosomal protein 
S6 (Hay and Sonenberg, 2004).  5’-TOP is a highly variable structure near the 5’-cap 
of mRNA and is overrepresented in transcripts that encode components of the 
translational machinery (Ruvinsky and Meyuhas, 2006).  However, genetic studies in 
mice revealed that 5’-TOP mRNAs are not regulated by S6K or S6, as translation of 
5’-TOP mRNAs is regulated normally in mouse embryonic fibroblasts (MEFs) from 
s6k1-/- and s6k2-/- double knockout mice (Pende et al., 2004) and in MEFs where S6 
cannot be phosphorylated (Ruvinsky et al., 2005). Therefore it remains unknown how 
mTOR regulates translation of 5’-TOP mRNA.  
 
S6k1-/- knockout mice are smaller and protected against obesity on a high fat 
diet, having smaller adipocytes and less white adipose tissue due to increased 
lipolysis (Um et al., 2004).  Furthermore, s6k1-/- knockout mice also have a reduced 
β-cell mass and thus, are limited in glucose uptake due to insufficient insulin 
secretion.  Due to a loss of IRS-1 (insulin receptor substrate) inhibition by S6K1, 
s6k1-/- knockout mice are hypersensitive to insulin.  S6K1 induces negative feedback 
inhibition towards insulin signaling by phosphorylating IRS-1 on Ser302, which blocks 
the interaction of the insulin receptor (IR) with IRS-1 and inhibits PI3K activation upon 
insulin stimulation (Harrington et al., 2004; Shah et al., 2004).  
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By destabilizing PDCD4 (programmed cell death protein 4), a tumor suppressor that 
prevents the interaction between eIF4A and eIF4G in a rapamycin-sensitive manner, 
S6K1 activates translation initiation (Dorrello et al., 2006).  To promote eIF4B 
recruitment to eIF4A, S6K1 also phosphorylates eIF4B on Ser 422 (Holz et al., 2005).  
S6K1 activates translation elongation by phosphorylation of eEF2K, the kinase that 
inhibits the eukaryotic elongation factor 2 (eEF2) (Wang et al., 2001).  S6K1 induces 
ribosome biogenesis via phosphorylation of the transcription factors UBF and TIF1A 
that mediate rRNA transcription (Hannan et al., 2003; Mayer et al., 2004).  S6K1 
phosphorylates mTOR in the repressor domain on Ser2448 (Chiang and Abraham, 
2005; Holz and Blenis, 2005).  
 
 
I.5.3  Akt/PKB 
 
Akt/PKB is an AGC kinase with a N-terminal pleckstrin homology (PH) domain that 
binds to PI3K-generated phosphatidylinositol (3,4,5) triphosphate (PIP3) and 
PI(3,4)P2 (PIP2) (Scheid and Woodgett, 2003).  Adjacent to the PH domain is the 
catalytic domain in Akt/PKB that contains a regulating T-loop.  Near the C-terminus in 
Akt/PKB lies a hydrophobic motif within a regulatory domain.   Mammals have three 
different Akt/PKB genes: Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ.  The three 
isoforms differ only slightly in sequence but their tissue-specific expression in mice 
correlates at least partially with their physiological importance (Yang et al., 2004).   
 
akt1-/-  knockout mice are small because of a nutrient shortage during 
development due to a smaller placenta (Yang et al., 2003).  akt2-/-  deficient mice are 
diabetic and develop hyperinsulinaemia, insulin resistance and glucose intolerance 
because insulin action in the liver and skeletal muscle is impaired, which results in 
defective glucose clearance from the blood (Cho et al., 2001).  In akt3-/-  mutant 
mice, brain size and weight are reduced by about 25% with preserved brain 
structures (Easton et al., 2005; Tschopp et al., 2005).  Creation of akt1-/- and akt2-/- 
double mutant mice and akt1-/- and akt3-/- double mutant mice revealed functional 
redundancy for the 3 Akt/PKB isoforms as the resulting double mutant phenotypes 
are more drastic than the assumed accumulation of the single mutant phenotypes.  
akt1-/- and akt2-/- double knockout mice die shortly after birth, are smaller and have 
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defects in the development of skin, bone, skeletal muscle and adipose tissue (Peng 
et al., 2003).  akt1-/- and akt3-/- double mutants are embryonically lethal (Yang et al., 
2004).  
 
Akt/PKB activation relies on its translocation to the plasma membrane via 
binding of its PH domain to PI3K-generated PIP3 and PIP2  (Andjelkovic et al., 1997).  
At the membrane, activation of Akt/PKB requires growth factor stimulated 
phosphorylation in its T-loop on Thr308 and in its hydrophobic motif on Ser473 
(Alessi et al., 1996).  PDK1 phosphorylates Thr308 in the T-loop of Akt/PKB (Alessi 
et al., 1997; Stephens et al., 1998; Williams et al., 2000).  Like Akt/PKB, PDK1 
possesses a PH domain and requires translocation to the plasma membrane via 
binding to PIP3 and PIP2 for the activation of Akt/PKB.  Only recently, mTORC2 was 
identified as the kinase complex that phosphorylates the hydrophobic motif on 
Ser473 in plasma membrane bound Akt/PKB (Sarbassov et al., 2005b).  
Phosphorylation of plasma membrane bound Akt/PKB on Ser473 requires additional 
PI3K activity in a manner that is distinct from Akt/PKB localization (Scheid et al., 
2002).  Whether phosphorylation in the T-loop of Akt/PKB depends on priming by 
phosphorylation in its hydrophobic motif, a hierarchy that is found in other AGC 
kinases, has been debated (Biondi et al., 2001).  Recent data from mTORC2-specific 
knockout mice provided evidence that Akt/PKB phosphorylation in the T-loop on 
Thr308 does not rely on a priori phosphorylation of Ser473 (Jacinto et al., 2006; 
Shiota et al., 2006).  Phosphorylation of the glycogen synthase kinase-3 (GSK-3) and 
tuberin (TSC2) by Akt/PKB occurs independently of Akt/PKB Ser473 
phosphorylation, whereas phosphorylation of FoxO1 and FoxO3a by Akt/PKB was 
lost upon lack of Ser473 phosphorylation that was due to a defect in mTORC2.  
Therefore, phosphorylation on Ser473 in Akt/PKB appears to specify Akt/PKB activity 
towards distinct substrate pools.  However, more recent data describes that the 
Akt/PKB-dependent phosphorylation sites in GSK-3 are phosphorylated by S6K1 in 
TSC deficient cells (Zhang et al., 2006a).  A better understanding of the physiological 
consequences of Akt/PKB Ser473 phosphorylation requires further examination to 
determine if GSK-3 is phosphorylated by Akt/PKB or S6K1 in mTORC2 deficient cells 
which lack Akt/PKB Ser473 phosphorylation.  
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Akt/PKB controls a wide range of cellular functions, including glycogen synthesis, cell 
growth, cell cycle, cell survival, and transcription via the phosphorylation of a growing 
list of direct substrates (Brazil and Hemmings, 2001; Fayard et al., 2005).  Highlights 
of Akt/PKB signaling include inhibition of GSK-3 via direct phosphorylation to regulate 
transcription and promote glycogen synthesis and protein synthesis (Frame and 
Cohen, 2001). Akt/PKB regulates cell cycle progression by phosphorylation of FoxO 
transcription factors and p27 (Brazil et al., 2004).  Akt/PKB-dependent 
phosphorylation of FoxO transcription factors and Bad prevents apoptosis.  Akt/PKB 
phosphorylates and inactivates TSC2, an upstream repressor of mTORC1, thereby 
promoting cell growth (Martin and Hall, 2005). 
 
 
Figure I-1. 
 
 
 
 
Figure I-1.  Signaling network downstream of mTOR (see I.4 and 1.5 for details).   
A dashed line with question mark illustrates a putative link without evidence.   
An arrowhead represents activation and a bar inhibition.  
 
 
I.6  Regulation of mTORC1 
 
mTORC1 is activated by growth factors, phorbol esters and amino acids, whereas 
low cellular energy and hypoxia inhibit mTORC1 (see Figure I-2). 
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I.6.1  Growth factors activate mTORC1 
 
Growth factors such as insulin induce rapamycin-sensitive phosphorylation of the 
mTORC1 readouts S6K and 4E-BP  via activation of PI3K (Hay and Sonenberg, 
2004; Thomas and Hall, 1997).  Upon extracellular binding of a growth factor to its 
receptor tyrosine kinase (RTK) the RTK dimerizes and the cytoplasmic tail of the 
transmembrane RTK is autophosphorylated (Weiss and Schlessinger, 1998).  RTK 
autophosphorylation recruits and activates the heterodimeric class Ia PI3K, a process 
that can involve a RTK specific adaptor molecule like the insulin receptor substrate 1 
(IRS-1) in the case of the insulin receptor (IR) (Engelman et al., 2006).  Upon 
activation, PI3K generates PI(3,4,5)P3 from PI(4,5)P2 by phosphorylating the D3 
position of the lipid.  The phosphatase and tensin homolog deleted on chromosome 
ten (PTEN) is a lipid phosphatase that counteracts PI3K signaling by 
dephosphorylating the D3 positions of PIP2 and PIP3.  
 
Genetic epistasis experiments in the Drosophila eye and wing revealed that 
dTSC1 (hamartin) and dTSC2 (tuberin) negatively regulate growth and that they 
signal between activated dPI3K and dS6K, downstream of dAkt and upstream of 
dTOR (Gao and Pan, 2001; Gao et al., 2002; Li et al., 2004; Potter et al., 2001; 
Tapon et al., 2001).  Hamartin (TSC1) and Tuberin (TSC2) are the two genes that 
were identified to cause the familial autosomal disorder tuberous sclerosis complex 
(TSC) (Consortium, 1993; van Slegtenhorst et al., 1997).  Hamartin has a potential 
transmembrane domain close to the N-terminus, a tuberin binding region and a coiled 
coil domain in the N-terminal part.  Tuberin has a predicted leucine zipper motive 
near the N-terminus, which is followed by two small coiled coil domains and a C-
terminal GAP domain. The N-terminus of tuberin binds to hamartin (Krymskaya, 
2003).  The TSC1-TSC2 complex forms rapidly after translation and is predominantly 
cytosolic (Nellist et al., 1999).  Mice deficient for tsc1-/- or tsc2-/- are embryonically 
lethal due to defective liver development (Kwiatkowski et al., 2002; Onda et al., 
1999).  In mammals, it was found that TSC1 and TSC2 interact (van Slegtenhorst et 
al., 1998) and together form the TSC1-TSC2 complex to inhibit mTORC1 signaling 
(Tee et al., 2002).  PI3K activation of TORC1 is mediated via TSC2 phosphorylation 
by Akt/PKB in flies and mammals, with the major sites being Ser939 and Thr1462 in 
human TSC2 (Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002).  
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Phosphorylation of TSC2 by Akt/PKB disrupts the interaction between TSC1 and 
TSC2, which inhibits the tuberous sclerosis complex (TSC1-TSC2) and leads to 
ubiquitin-mediated TSC2 degradation (Benvenuto et al., 2000).  
 
TSC1-TSC2 inhibits TOR in mammals and Drosophila by negatively regulating 
the TOR activator Rheb (Ras homolog enriched in brain) (Manning and Cantley, 
2003), a small GTP-binding protein.  Via a GAP (GTPase activating protein) domain 
in TSC2, the TSC1-TSC2 complex activates the GTPase in Rheb (Garami et al., 
2003; Inoki et al., 2003a; Tee et al., 2003b; Zhang et al., 2003b), which results in 
Rheb inactivation due to GDP (guanosyl diphosphate) binding.  Insulin stimulates 
Rheb GTP (guanosyl triphosphate) binding (Garami et al., 2003) and GTP bound 
Rheb activates the TORC1 targets S6K and 4E-BP in mammals and Drosophila even 
in the absence of growth factors (Garami et al., 2003; Inoki et al., 2003a; Saucedo et 
al., 2003; Stocker et al., 2003; Tee et al., 2003b; Zhang et al., 2003b).   
 
Growth factor binding to RTK also activates the MAPK (mitogen-activated 
protein kinase) signaling cascade via the kinases Ras and Raf towards MEK1/2 
(MAPK/ERK kinases 1 and 2), stimulating ERK1/2 (extracellular-signal related 
kinases 1 and 2) (Roux and Blenis, 2004; Shaw and Cantley, 2006).  The RTK 
recruits the Ras GEF son-of-sevenless (SOS) for activation of Ras.  In addition to 
RTK activation, phorbol esters strongly stimulate ERK1/2 by recruiting the Ras 
guanyl nucleotide-releasing protein (RasGRP), which functions as a Ras GEF 
(Roose and Weiss, 2000).  Activation of the MAPK cascade induces phosphorylation 
of human TSC2 on Ser540 and Ser664 by ERK1/2 and on Ser1798 by the p90 
ribosomal S6K1 (RSK1), which is an ERK1/2 substrate (Ma et al., 2005a; Roux et al., 
2004).  Phosphorylation of TSC2 on Ser540, Ser664 and Ser1798 inactivates the 
TSC1-TSC2 complex. Besides mTORC1 activation by ERK1/2-dependent 
phosphorylation of TSC2 there is evidence that ERK1/2 signals also to complement 
mTORC1 signaling, as it is found for translational regulation of LTP in hippocampal 
neurons (Kelleher et al., 2004) and for the redundant phosphorylation of the S6K site 
Ser422 in eIF4B by RSK1 (Shahbazian et al., 2006).  
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I.6.2  Amino acids activate mTORC1 
 
Amino acids, leucine in particular, stimulate the phosphorylation of the mTORC1 
readouts S6K and 4E-BP in a rapamycin-sensitive manner (Anthony et al., 2000; 
Hara et al., 1998).  Upon amino acid starvation, S6K and 4E-BP are 
dephosphorylated and become unresponsive to insulin stimulation.  Amino acids 
were initially thought to signal via TSC1-TSC2 in Drosophila and mammals because 
TSC mutant cells show a certain resistance against amino acid deprivation (Gao et 
al., 2002) and overexpression of TSC1/2 partially inhibits amino acid stimulation 
towards mTORC1 readouts (Tee et al., 2002).  However, several findings suggest 
that amino acids signal rather directly via Rheb (Ras homolog enriched in brain), and 
not via TSC1-TSC2.  First, amino acid starvation inhibits mTORC1 signaling even in 
tsc2 mutant cells (Smith et al., 2005).  Second, Rheb overexpression is sufficient to 
bypass repression from amino acid starvation on mTORC1 readouts (Garami et al., 
2003; Inoki et al., 2003a; Saucedo et al., 2003; Stocker et al., 2003; Tee et al., 
2003b).  And third, Rheb binds directly to mTOR, independently of nucleotide binding 
but sensitive to amino acids (Long et al., 2005a; Long et al., 2005b). Rheb GTP 
charging affects mTOR kinase activity.  These findings argue towards two parallel 
paths for the regulation of Rheb, one induced by growth factors that stimulate Rheb 
GTP levels via TSC1-TSC2 and the other induced by amino acids that regulate Rheb 
binding to mTOR.  However, our knowledge on how amino acids signal into the TOR 
pathway is still incomplete and in certain aspects contradictory.  Like for amino acids, 
the interaction between Rheb and mTOR has been reported to be sensitive to TSC1-
TSC2 (Smith et al., 2005).  Also, it is still not clear whether amino acids affect GTP 
charging of Rheb or not (Long et al., 2005b; Smith et al., 2005; Zhang et al., 2003b).  
 
Rheb has a mammalian homolog, RhebL1 (Rheb-like 1), that is conserved in 
structure, function and regulation (Tee et al., 2005).  The switch I region and the Ec 
region of Rheb and RhebL1 have conserved residues that enable specific mTOR 
interaction and are not found in the according regions in Ras.  The switch I region in 
Ras changes its conformation depending on the nucleotide to which it binds and the 
Ec (constitutive effector) region is required for Ras activity.  Rheb activity towards 
mTORC1 depends further on farnesylation, and thus requires membrane localization 
(Tee et al., 2003b). 
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Recently, it has been described that hVps34, a class III PI3K, activates mTORC1 
(Byfield et al., 2005) and mediates the amino acid stimulation towards mTORC1 
readouts (Nobukuni et al., 2005).  The function of class III PI3Ks is not well 
understood in mammals but it is known that beclin-1 induces autophagy when bound 
to hVps34 (Engelman et al., 2006; Meijer and Codogno, 2006).  If amino acids 
generally activate or inhibit Vps34 remains contradictory, and the answer may be that 
different pools of class III PI3K with different functions do not respond uniformly to 
amino acids (Dann and Thomas, 2006).  
 
 
I.6.3  Energy activates mTORC1 
 
Energy activates mTORC1 in a way that low cellular energy levels inhibit mTORC1 
via activation of the AMP-activated protein kinase (AMPK) (Hardie, 2005).  The 
regulatory γ-subunit of the heterotrimeric AMPK binds AMP and with lower affinity 
ATP.  Binding of AMP induces allosteric activation of AMPK to allow phosphorylation 
of AMPK on Thr172 by the tumor suppressor LKB1 that is needed for AMPK 
activation (Hardie et al., 2006).  Activated AMPK phosphorylates human TSC2 on 
Ser1337, Ser1341 and Ser1345 and thereby activates TSC1-TSC2, which leads to 
mTORC1 inhibition (Inoki et al., 2003b).  Mutations in LKB1 can hyperactivate 
mTORC1 and cause the Peutz-Jegher syndrome (PJS), a familial autosomal disorder 
that shows similarity to TSC (Corradetti et al., 2004; Shaw et al., 2004).  Glucose 
deprivation and hypoxia physiologically activate AMPK in glucose sensing and 
oxygen consumpting tissue, respectively.  Furthermore, it has been shown that 
AMPK activity is regulated by adipokines and that this regulation can be either 
positive or negative, depending on the tissue (Hardie et al., 2006).  In skeletal muscle 
and liver, the adipokines leptin and adiponectin stimulate AMPK to increase fatty acid 
oxidation and induce mitochondrial biogenesis.  Conversely, leptin inhibits AMPK in 
the hypothalamus to reduce food intake (Kahn et al., 2005).  The mechanism of how 
AMPK stimulates feeding behaviour is potentially linked to the inhibitory effect of 
AMPK towards mTORC1 in the hypothalamus (Cota et al., 2006). 
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AMPK-dependent phosphorylation of TSC2 on Ser1345 primes TSC2 for additional 
phosphorylation by GSK-3 on Thr1329, Ser1333, Ser1337 and Ser1341 to further 
activate TSC1-TSC2 (Inoki et al., 2006).  Wnt-3a negatively regulates GSK-3 and 
prevents TSC2 phosphorylation by GSK-3.  GSK-3 also phosphorylates TSC1 on 
Thr357 and Thr390 to stabilize the TSC1-TSC2 complex (Mak et al., 2005). 
 
 
I.6.4  Hypoxia inhibits mTORC1 
 
Hypoxia inhibits mTORC1 regulated protein synthesis in three ways (Bernardi et al., 
2006; Pouyssegur et al., 2006).  Hypoxia inhibits mTORC1 as TSC1-TSC2 is 
activated via stimulation of AMPK that results from increasing AMP levels (Hardie, 
2005; Liu et al., 2006).  Hypoxia inhibits mTORC1 also by inducing expression of the 
HIF-1 responsive genes REDD1 and REDD2 (Brugarolas et al., 2004), which are 
orthologs of the redundant growth suppressors Scylla and Charybdis in Drosophila 
(Reiling and Hafen, 2004) and activate TSC1-TSC2.  Furthermore, hypoxia inhibits 
mTORC1 via the promyelotic leukaemia (PML) tumor suppressor that interferes with 
Rheb binding to mTOR, independently of TSC1-TSC2 (Bernardi et al., 2006).  As 
hypoxic inhibition of mTOR is mediated by TSC1-TSC2, it appears that TSC1-TSC2 
integrates signals from growth factors and cellular energy into the hypoxic response.   
Indeed, cells deficient in TSC2 or PTEN show increased mTORC1 activity during 
hypoxia (Kaper et al., 2006).  
 
The finding that mTORC1 maintains the hypoxic response by positively 
regulating HIF-1 (see mTORC1 functions) does not fit at first glance with the finding 
that hypoxia inhibits mTORC1.  Nevertheless, it reminds one of a fuse-like control 
mechanism.  An explanation to this confusing signal transduction might be that 
autophagy, which is induced by mTORC1 inhibition, is required to maintain energy 
homeostasis during hypoxia but apparently, autophagy needs to be tightly controlled 
in order to provide a benefit to the cell.  Autophagy is a self limited survival strategy, 
resulting in cell death if not reversed, and the recovery from the catabolic effects 
takes several days (Lum et al., 2005; Pouyssegur et al., 2006).  Hypoxia does not 
completely shut down mTORC1 activity (Kaper et al., 2006) and a negative feedback 
signal from mTORC1 to reduce hypoxic stimulation could provide the regulatory 
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mechanism needed for autophagy control and keep the cells responsive to growth 
factors during hypoxia. 
 
 
I.6.5  Further regulation of mTORC1  
  
Recently, it was shown that the intermediate filament keratin 17, which is rapidly 
induced in wounded epithelia, is required for mTOR-dependent protein synthesis 
(Kim et al., 2006).  Keratin 17 would maintain growth by regulating the cytoplasmic 
localization of 14-3-3σ.  
Furthermore, p53 inhibits mTORC1 upon DNA damage via TSC1-TSC2 (Feng et al., 
2005).  
 
 
I.7  Regulation of mTORC2 
 
If and how mTORC2 signaling is regulated is still unclear (see Figure I-2).  Growth 
factors stimulate the mTORC2 readouts actin organization, cell spreading and 
Akt/PKB phosphorylation (Jacinto et al., 2006; Jacinto et al., 2004; Sarbassov et al., 
2004; Sarbassov et al., 2005b).  Growth factors that stimulate mTORC2 readouts 
also inactivate the TSC1-TSC2 complex but it has been suggested that TSC1-TSC2 
would activate mTORC2.  Indeed, TSC deficiency or Rheb stimulation exert an 
inhibitory effect on the insulin pathway, but this is caused indirectly by negative 
feedback inhibition from hyperactivated mTORC1-S6K1 to IRS-1 (see also I.5.2).  
Because such negative feedback inhibition blocks insulin stimulation towards the 
mTORC2 readout Akt/PKB phosphorylation on Ser473, Yang et al. suggested that 
TSC1-TSC2 activates mTORC2 and Rheb inhibits mTORC2, which would be 
opposite to the regulation of mTORC1 (Yang et al., 2006).  However, even in TSC 
deficient cells mTORC2 phosphorylates Akt/PKB on Ser473 either upon stimulation 
with the IRS-1 independent growth factor EGF (epidermal growth factor) or upon 
insulin stimulation while mTORC1-S6K1 is inhibited (Harrington et al., 2004; Yang et 
al., 2006).  Therefore, TSC1-TSC2 is not a required activator for mTORC2 as Yang 
et al. proposed.  Yet, it may well be that the contrary of what Yang et al. have 
proposed is true, in that TSC1-TSC2 inhibits mTORC2 activity based on the 
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coincidence that mTORC2 signals upon stimuli such as insulin that inhibit TSC1-
TSC2.  The result section in this thesis provides evidence that mTORC2 is indeed 
inhibited by TSC1-TSC2.  
 
 
Figure I-2. 
 
 
 
 
Figure I.2.   Network of mTOR regulation (see I.6 and 1.7 for details). 
A dashed line with question mark illustrates a putative link without evidence.   
An arrowhead represents activation and a bar inhibition.  
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I.8  mTOR related diseases 
 
Several human diseases result from tissue overgrowth with a link to the mTOR 
signaling pathway.  Typically, mTOR hyperactivation is caused by inactivating 
mutations of suppressors in the mTOR pathway like the TSC1-TSC2 complex, LKB1 
or PTEN, resulting in mTOR-dependent overgrowth.  Due to a feedback regulatory 
mechanism in the mTOR pathway, mutations in TSC1-TSC2 and LKB1 do not 
necessarily lead to malignant progression.  However, combined hyperactivation of 
mTOR and PI3K due to PTEN deficiency bypass the feedback checkpoint and have 
been observed in many cancers that show a severe rate of malignancy. 
 
 
I.8.1  Tuberous Sclerosis Complex  
 
Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor suppressor 
gene syndrome with a prevalence of about 1 in 6000 that causes hamartomas 
(benign tumors) and hamartias (malformations) in multiple tissues with a highly 
variable clinical manifestation among different patients (Kwiatkowski et al., 2002).  
Prominent hamartomas in TSC are cortical tubers that appear during embryogenesis 
and later in life cause seizures, mental retardation and behavioural disorders (Onda 
et al., 2002).  The most frequent tumors in TSC include subependymal giant cell 
astrocytomas (SEGAs) in the cortex, facial angiofibromas in the skin, cardiac 
rhabdomyomas in the juvenile heart, and renal angiomyolipomas in the kidney.  
Inactivating mutations in either TSC1 or TSC2 occur sporadic in about two-thirds of 
TSC patients. In sporadic TSC, TSC2 is mutated about 5 times more often (4,2 : 1) 
than TSC1, whereas this ratio is 1 : 1 in inherited TSC (Kwiatkowski and Manning, 
2005).  A broad spectrum of mutations is spanning along the entire TSC1 and TSC2 
genes that can lead to TSC, including missense mutations, in frame deletions and 
large deletions.  Although there are no dramatic hotspots, several warmspots are 
apparent, one of them being the GAP domain in TSC2 (Kwiatkowski, 2003; 
Maheshwar et al., 1997).  Hamartoma development in TSC is often linked to allelic 
loss of heterozygosity (LOH) but some tubers do not show evidence for LOH or a 
classical second hit inactivation within the corresponding allele (Kwiatkowski and 
Manning, 2005).  A second hit mechanism that involves other signaling pathways has 
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been suggested for brain regions in TSC because SEGAs often lack LOH of TSC but 
instead express high levels of activated Akt/PKB and activated ERK1/2.  Such a 
mechanism is plausible and can experimentally be reproduced by combining 
heterozygous tsc2+/- mice with pten+/- heterozygosity, which dramatically increases 
tumorigenesis in comparison to mice that are only tsc2+/- heterozygous (Ma et al., 
2005b; Manning et al., 2005).  These experiments also provided an explanation for 
the low rate of progression to malignancy that is observed in TSC patients (Al-
Saleem et al., 1998).  Activation of Akt/PKB upon stimulation with serum or growth 
factors is strongly impaired in TSC1-TSC2 deficient cells as well as in tissue from 
heterozygous tsc2+/- mice.  The lack in Akt/PKB activation is a consequence of the 
downregulation of the platelet-derived growth factor receptor (PDGFR) (Zhang et al., 
2003a) and the inhibition of IRS-1 in TSC deficient cells (Harrington et al., 2004; 
Shah et al., 2004).  In-vivo, the combination of heterozygous tsc2+/- mice with 
pten+/- heterozygosity results in restored Akt/PKB activation and more severe tumor 
growth.  
 
Hyperactivation of mTORC1 can be observed in TSC lesions and is suspected 
to contribute in large to the clinical syndromes in TSC (Chan et al., 2004).  
Apparently, pre-clinical data promises that the use of mTOR inhibitors to treat TSC is 
beneficial for patients (Lee et al., 2005a).  In addition, farnesyltransferase inhibitors 
promise to be useful drugs against TSC due to Rheb inactivation (Gau et al., 2005). 
 
 
I.8.2  Autosomal-dominant polycystic kidney disease 
 
TSC patients are prone to develop autosomal-dominant polycystic kidney disease 
(ADPKD) because large deletion mutations in TSC2 can affect the adjacent PKD1 
(Polycystic Kidney Disease 1, or also called Polycystin-1 (PC-1)) gene on 
chromosome 16, a major contributor to ADPKD (Sampson et al., 1997).  Patients with 
ADPKD develop renal cysts that lead to renal failure.  The clinical use of rapamycin 
analogs for immunosuppression in kidney transplantation suggested that mTOR 
inhibition reduces growth of renal sarcomas, which led to the hypothesis that 
inhibition of mTOR could also be beneficial for the treatment of ADPKD.  In animal 
models for ADPKD, mTOR hyperactivation was observed and mTOR inhibition could 
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indeed retard cyst formation and progression of renal failure, which suggests that 
mTOR activity is a molecular mechanism underlying renal cyst formation (Tao et al., 
2005; Wahl et al., 2006).  Recently, hyperactivated mTOR was found in cyst-lining 
epithelial cells in human ADPKD patients and it was suggested that Polycystin-1 
(PC1) activates mTOR by binding to TSC2 (Shillingford et al., 2006).  PC1 mutations 
are frequently found in ADPKD.  
 
 
I.8.3  Lymphangioleiomyomathosis 
 
Pulmonary lymphangioleiomyomathosis (LAM) is a lung lesion caused by infiltrating 
and proliferating smooth muscle cells and epitheloid cells that form cysts and destroy 
airways (Kwiatkowski and Manning, 2005).  LAM is a gender-specific disease that is 
rarely detected in men (Aubry et al., 2000).  The gender-specificity appears to relate 
to a high expression of receptors for estrogen and progesterone in LAM cells 
because estradiol stimulates the growth of TSC2 mutant cells (Astrinidis and Henske, 
2005).  LAM occurs in about half of the female TSC patients but clinical syndromes 
develop only in about 5-10 % of adult females with TSC.  Occasionally, LAM occurs 
sporadic in patients without TSC, but also sporadic LAM is caused by LOH in either 
TSC1 or TSC2 (Carsillo et al., 2000; Sato et al., 2002; Sato et al., 2004).  Pulmonary 
LAM cells are identical in their TSC mutations and LOH pattern with benign 
angiomyolipoma smooth muscle cells in other organs of LAM patients, suggesting 
that benign cells with mutations in either TSC1 or TSC2 metastasize from outside 
into the lungs (Henske, 2003).  The observation of recurrent recipient LAM cells in 
donor lungs after lung transplantation clearly demonstrates that TSC deficient cells, 
which are histologically benign, do metastasize in-vivo (Karbowniczek et al., 2003).  
In-vitro it has also been found that TSC deficient cells migrate aberrantly (Astrinidis 
and Henske, 2005) and hamartin and tuberin activate members of the Rho GTPase 
superfamily that regulate actin polymerization, cell morphology and migration.  
Reports concerning the role of TSC1 and TSC2 in migration do not completely 
overlap in their findings and thus the exact mechanism is still not understood.  One 
study found that overexpression of TSC1 activates Rho, which reduces cell migration 
(Lamb et al., 2000) and a similar result was obtained for overexpression of TSC2 
(Astrinidis et al., 2002).  However, in LAM cells it was shown that Rho inhibition 
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decreases cell migration and that TSC1 activates RhoA if TSC2 is deficient in binding 
TSC1 (Goncharova et al., 2006a).  
 
mTORC1 hyperactivation contributes to the increased growth rate of LAM cells 
and inhibition of mTORC1 reduces LAM cell growth.  Therefore, mTOR inhibition 
appears as a promising therapeutic strategy for the treatment of LAM (Goncharova et 
al., 2006b).  
 
 
I.8.4  Other hamartoma syndromes 
 
Cowden’s disease, Lhermitte-Duclos disease, Bannayan-Zonana syndrome and 
Proteus syndrome are hamartoma syndromes that share similarities to TSC although 
they result from inactivating mutations in the tumor suppressor PTEN.  Because of 
the similarities to TSC and the fact that PTEN deficiency results in TSC1-TSC2 
inhibition and thus mTORC1 hyperactivation, it may be pharmacologically beneficial 
to consider the inhibition of mTORC1 signaling as therapeutic strategy in the 
treatment of such diseases (Inoki et al., 2005; Tee and Blenis, 2005). 
 
In Peutz-Jeghers syndrome (PJS), hamartomas form in skin and intestine and 
the patients are prone to develop tumors.  Also in PJS, mTORC1 hyperactivation is 
thought to contribute to the disease because PJS results from an inactivating 
mutation in LKB1, which is needed for AMPK activation and thus negative regulation 
of mTORC1 (Inoki et al., 2005; Tee and Blenis, 2005). 
 
 
I.8.5  Cancer 
 
PTEN deficiency is associated with the tumorigenesis of many different cancers like 
endometrial cancer, breast cancer glioblastoma, prostate-, ovarian-, thyroid- and 
hepatocellular carcinoma.  mTOR inhibition promises to be a well tolerated and 
beneficial therapeutical strategy in PTEN deficient tumors, which is suggested by 
several clinical studies (Faivre et al., 2006).  Since Akt/PKB hyperactivation is one of 
the molecular hallmarks in PTEN deficient tumors and contributes to cancer growth, 
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the Akt/PKB activating mTORC2 is also considered as a possible new target in anti-
cancer intervention (Guertin and Sabatini, 2005).  Patients with renal cell carcinoma 
already benefit from therapeutic mTORC1 inhibition and the clinical history of 
rapamycin analogues as immunosuppressants after kidney transplantation (Faivre et 
al., 2006).  Furthermore, rapamycin analogues could be beneficial for the treatment 
of metastatic tumor growth in general as they inhibit neoangiogenesis by reducing 
secretion of VEGF (vascular endothelial growth factor) (Guba et al., 2002; Tee and 
Blenis, 2005).  Also in cancers that show elevated 5’-cap-dependent translation due 
to a hyperactive eIF4F complex, rapamycin analogues are expected to contribute to a 
better disease prognosis (Mamane et al., 2004; Shaw and Cantley, 2006).  
 
 
I.8.6  Neurodegeneration 
 
In the brain, autophagy is a protective mechanism against neurodegenerative 
diseases such as Parkinson, Alzheimer and Huntington because these diseases 
develop from accumulating defective proteins (Meijer and Codogno, 2006).  
Neurodegeneration appears as a consequence of deficient autophagy in mouse 
neurons (Hara et al., 2006; Komatsu et al., 2006).  Induction of autophagy by mTOR 
inhibition in animal models suggest beneficial support in the clearance of protein 
aggregates that are involved in the development of Huntington’s disease and 
Alzheimer’s disease (Berger et al., 2006; Ravikumar and Rubinsztein, 2006; 
Ravikumar et al., 2004). 
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II.  Materials and Methods 
 
 
Chemicals and Antibodies. Cell culture reagents, puromycin, tetracycline and 
insulin were obtained from Sigma; blastocidin and  zeocin from Cayla; U0126 and 
LY294002 from Alexis; rapamycin from LC Laboratories; HRP-coupled anti-mouse 
and anti-rabbit secondary antibodies from Pierce; HRP-coupled anti-goat secondary 
antibody from Sigma; anti-Paxillin-pY118, anti-Paxillin, anti-PKB-pS473, anti-S6K-
pT389, anti-S6K and anti-Erk1/2-pT202/Y204 were from Cell Signaling Technology; 
anti-PKB and anti-Rheb from Santa Cruz; anti-4E-BP1 from Zymed; anti-actin 
(MAB1501) from Chemicon; anti-GFP from Roche.  Anti-rictor and anti-raptor were 
produced as described (Jacinto et al., 2004).  We generated polyclonal anti-TSC1 
and anti-TSC2 as described (van Slegtenhorst et al., 1998).  Plasmids for TSC 
antigen generation were kindly provided by Dr. Mark Nellist. Anti-HA was from 
concentrated 12CA5 tissue culture supernatant.   
 
Plasmids.  pTER was a kind gift from Dr. Mark van de Wetering (Centre for 
Biomedical Genetics, Utrecht, The Netherlands) (van de Wetering et al., 2003); 
pKDM-175 is a pTER-based  siRNA expressing plasmid targeting 
gacacacagaatagctatg in TSC1 mRNA; pKDM-185 is a pTER-based plasmid targeting 
gtcctgcagtggatggatg in TSC2 mRNA; pKDM-176 is a LxSP-based plasmid (with 
puromycin resistance cassette) constructed by inserting the EcoRI fragment 
containing the tetracycline inducible siRNA cassette from pKDM-175; pKDM-132 is a 
pSuper.gfp/neo-based (Oligoengine) siRNA expressing plasmid targeting 
ctgtgaactagcacttcag in rictor mRNA; pKDM-162 is a pSuper.gfp/neo-based 
(Oligoengine) siRNA expressing plasmid targeting ggacaacggccacaagtac in raptor 
mRNA; pKDM-212 is a pSuper.gfp/neo-based plasmid targeting gcgagttcgtgtcatcgag 
for non-specific control siRNA in human cells (oligos were kindly provided by Jean 
Pieters); HA-myr-PKB was a kind gift from Dr. Brian Hemmings (Andjelkovic et al., 
1997); myc-Rheb was a kind gift from Dr. George Thomas (Garami et al., 2003). 
GST-RhebL1 and Flag-RhebL1 were kind gifts from Dr. Andrew Tee (Tee et al., 
2005). silent point mutations were inserted into the siRNA target regions of full-length 
TSC1 and TSC2 pcDNA3.1-based constructs (kind gifts from Dr. Mark Nellist) (van 
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Slegtenhorst et al., 1998) using the QuickChange method (Stratagene) with the 
primer pairs: 5’-gcccttatgctgatactcaaaatagctatggg-3’/5’-cccatagctattttgagtatcagcataag 
ggc-3’ for TSC1 and 5’-ggctgactttgtgctccaatggatggatgttggc-3’/5’-gccaacatccatccattgg 
agcacaaagtcagcc-3’ for TSC2. 
 
Cell culture and transfections.  Cells were maintained in D-MEM containing 10% 
fetal bovine serum and Penicillin/Streptomycin.  TSCsi293 cells were induced for 96 
hours with tetracycline (4 µg/ml) to knock down TSC1 and TSC2 protein levels.  Cells 
were stimulated in D-PBS+ (D-PBS, 1x MEM Vitamin mix, 1000 mg/l D-Glucose and 
Penicillin/Streptomycin) supplemented as indicated with 10% fetal bovine serum, 
amino acids (1x MEM essential amino acid mix and 1x MEM non-essential amino 
acid mix), 100 nM insulin or inhibitors (in DMSO as vehicle).  For overnight serum 
deprivation, HEK293T cells were grown for 17 hours in D-MEM containing 
Penicillin/Streptomycin without serum.  For transfection, cells were split in 6-well 
plates (+/- tetracycline in case of TSCsi293 cells) before transfection 24h later with 
8µl Lipofectamine 2000 (Invitrogen) and 3µg DNA per well, following the 
manufacturer’s guidelines.  Two hours later, the cells were split again in fresh 
medium (+/- tetracycline in case of TSCsi293 cells) and cultured for another 48 hours 
prior to stimulation.  For cell lysis, cells were rinsed on ice with PBS before scraping 
them in ice-cold TNE lysis buffer (50 mM Tris-HCl pH8.0, 150 mM NaC, 0,5 mM 
EDTA, 1% Triton x100) supplemented with protease and phosphatase inhibitors (1x 
Roche complete protease inhibitor cocktail, 1 µg/ml Aprotinin, 1 µg/ml Pefabloc, 1 
mM PMSF, 10 mM NaF, 10 mM NaN3,  10 mM NaPPi, 10 mM B-glycerophosphate, 
10 mM p-nitrophenylphosphate).  After 20 minutes of incubation, cell debris was 
removed by centrifugation for 5 minutes at 7000g. The protein concentration was 
determined with a Bio-Rad assay and equalized.  For Western blotting, SDS-PAGE 
sample buffer was added and the probes were heated for 5 minutes at 950C. 
 
Generation of a stable TSCsi293 cell line. 293T-REx cells which stably express the 
tetracycline repressor (TetR) (Invitrogen) were a kind gift from Martin Spiess.  The 
cells were transfected with pKDM-176 and pKDM-185 and selected for resistance to 
blasticidin (10 µg/ml), zeocin (300 µg/ml) and puromycin (1 µg/ml) to generate 
clones.  Individual clones were picked, expanded, and tested for tetracycline-
inducible siRNA knockdown of TSC1 and TSC2 by Western blotting.  To control that 
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tetracycline treatment or expression of non-targeted siRNA did not interfere with the 
studied signalling pathway, we confirmed in control experiments that tetracycline 
treatment and non-specific siRNA expression in 293T-REx cells did not affect 
phosphorylation of Paxillin Tyr118, Akt/PKB Ser473 or S6K Thr389. 
 
Immunoprecipitation and Western blotting.  To immunoprecipitate HA-tagged 
protein, 2 µl of anti-HA antibody was added to 300 µl of cell lysate containing 500 µg 
of total protein and rotated for one hour at 40C.  20 µl of protein G-Sepharose slurry 
(Sigma) was added to the mix and rotation continued for another hour before the 
beads were washed three times with lysis buffer.  Beads were collected by 
centrifugation, resuspended in 2x SDS-PAGE sample buffer and heated for 5 
minutes at 950C.  The supernatant was transferred to a fresh tube and stored at -
200C before aliquots were analysed by Western blotting.  For Western blotting, 60-
100 µg of protein of cell lysate per lane were electrophoresed in SDS-PAGE mini 
gels and transferred to nitrocellulose.  The manufacturer’s guidelines were followed 
for antibody incubations.  SuperSignal West Pico and Femto kits (Pierce) were used 
for ECL-detection. 
 
Quantification of cell spreading.  Cells were grown on coverslips and fixed in 4% 
PFA. Rhodamine-phalloidine and DAPI (Sigma) were used to stain F-actin and 
nuclei, respectively.  Cells were analysed using a Zeiss Axioplan microscope.  Only 
cells that showed an intact nucleus by DAPI staining were counted.  Cells were 
considered spread if there was at least one lamellipodia-like extension with a minimal 
width of the nuclear radius. 
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III.  TSC1-TSC2 complex inhibits mTORC2 in human cells 
 
 
III.1  Introduction 
 
The conserved serine/threonine kinase mTOR is a central regulator of eukaryotic cell 
and organismal growth (Wullschleger et al., 2006).  mTOR is found in two structurally 
and functionally distinct protein complexes, mTORC1 and mTORC2 (Loewith et al., 
2002; Sarbassov et al., 2005a).  Rapamycin-sensitive mTORC1 consists of mTOR, 
raptor, and mLST8, and controls a wide range of cellular processes including 
translation, transcription, nutrient transport, ribosome biogenesis and autophagy.  
The two best characterized effectors of mTORC1 are S6K and 4E-BP1, which 
mTORC1 phosphorylates directly to activate translation (Hay and Sonenberg, 2004).  
Rapamycin-insensitive mTORC2 consists of mTOR, rictor, and mLST8.  mTORC2 
appears to control organization of the actin cytoskeleton and cell spreading via 
activation of Paxillin (Tyr118 phosphorylation), Rho, Rac, and PKC (Jacinto et al., 
2004; Sarbassov et al., 2004).  The mechanism by which mTORC2 activates these 
effectors is unknown but must be indirect at least in the case of Paxillin which is 
activated by tyrosine phosphorylation. mTORC2 directly phosphorylates Ser473 in 
the hydrophobic motif of Akt/PKB and thereby activates Akt/PKB towards a FoxO 
transcription factor (Sarbassov et al., 2005b). 
 
mTORC1 is regulated in response to nutrients (amino acids), growth factors 
(insulin/IGF-1), cellular energy status (AMPK), and stress  (Wullschleger et al., 2006).  
Growth factors stimulate mTORC1 via the phosphoinositide 3-kinase (PI3K) pathway 
(Shaw and Cantley, 2006).  PI3K produces PtdIns(3,4,5)P3 (PIP3) from PtdIns(4,5)P2 
(PIP2), which in turn recruits PKB and PDK1 to the plasma membrane (Fayard et al., 
2005).  At the plasma membrane, PDK1 activates Akt/PKB by phosphorylating 
Thr308 in the activation loop of Akt/PKB (Lizcano and Alessi, 2002).  Akt/PKB 
phosphorylates TSC2 (Tuberin) and thereby inhibits TSC1-TSC2, a hetero-dimeric 
GAP (GTPase activating protein) for the small GTPase Rheb (Shaw and Cantley, 
2006).  Inhibition of TSC1-TSC2 results in increased levels of GTP bound Rheb.  
Rheb-GTP binds and activates mTORC1. Independent of PI3K, the MAP kinases 
ERK1 and 2 also phosphorylate TSC2 and inactivate TSC1-TSC2 (Ma et al., 2005a; 
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Tee et al., 2003a).   Loss-of-function mutations in TSC1 or TSC2 cause 
hyperactivation of mTORC1 and lead to various syndromes characterized by cell 
overgrowth, such as Tuberous Sclerosis Complex (TSC) and 
Lymphangioleiomyomatosis (LAM) (Kwiatkowski and Manning, 2005; Tee and Blenis, 
2005).  Amino acids stimulate mTORC1 via an unknown mechanism involving Rheb 
and possibly TSC1-TSC2 (Wullschleger et al., 2006). 
 
Rapamycin-insensitive mTORC2 was discovered only recently and its 
upstream regulators are thus largely unknown.  mTORC2 readouts such as actin 
organization, cell spreading, and Akt/PKB-Ser473 phosphorylation are stimulated by 
growth factors (serum or insulin), suggesting that mTORC2 may be activated by 
growth factors (Jacinto et al., 2004).  This in turn suggests that mTORC2, like 
mTORC1, is inhibited by TSC1-TSC2.   However, Yang et al. (Yang et al., 2006) 
have reported recently that loss of TSC1/2 results in loss of insulin-stimulated 
Akt/PKB Ser473 phosphorylation, suggesting that mTORC2, contrary to mTORC1, is 
activated by TSC1-TSC2.  As Yang et al. (Yang et al., 2006) propose, this apparent 
paradox may be explained by a negative feedback loop from mTORC1-S6K to IRS-1 
upstream of PI3K in the insulin signaling pathway.  S6K, activated in TSC mutant 
cells, phosphorylates and inhibits IRS-1 (Harrington et al., 2004; Shah et al., 2004; 
Um et al., 2004).  This results in down regulation of the insulin signaling pathway, 
including down regulation of PI3K and Akt/PKB Ser473 phosphorylation (Manning, 
2004).  Loss of Ser473 phosphorylation in this context could be due to loss of 
mTORC2 kinase activity or, alternatively, due to loss of insulin stimulated recruitment 
of Akt/PKB to the plasma membrane (Andjelkovic et al., 1997; Inoki and Guan, 2006). 
The observation that rapamycin treatment, which inhibits mTORC1 and the negative 
feedback loop to IRS-1, restores Akt/PKB Ser473 phosphorylation in insulin treated 
TSC mutant cells suggests that loss of TSC does not cause loss of rapamycin-
insensitive mTORC2 activity (Harrington et al., 2004; Yang et al., 2006).  The 
observation that stimulation of the PI3K pathway with EGF, which does not involve 
IRS-1 and is thus not subject to the negative feedback loop, induces Ser473 
phosphorylation in TSC mutant cells is further evidence that TSC1-TSC2 is not 
required for mTORC2 activity (Harrington et al., 2004). It is also worth noting that the 
experiments of Yang et al. (Yang et al., 2006) were performed largely in Drosophila 
S2 cells which seem to have a particularly robust negative feedback loop.  Thus, loss 
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of TSC may cause loss of insulin stimulated Ser473 phosphorylation due to loss of 
Akt/PKB localization to the plasma membrane.  Although it appears that TSC1-TSC2 
is not required for mTORC2 activity, it remains to be determined whether mTORC2, 
like mTORC1, is inhibited by TSC1-TSC2. 
 
To investigate the regulation of mTORC2 and, in particular, the role of TSC1-
TSC2 in this regulation, we created a HEK293T derived cell line (TSCsi293) that 
allows stable, inducible siRNA mediated knockdown of TSC1 and TSC2.  This cell 
line was used to assay the effect of TSC1/2 knockdown on physiological mTORC2 
readouts that are not subject to the confounding effects of the negative feedback loop 
in the insulin pathway.  To circumvent the effect of the negative feedback loop on 
Akt/PKB localization, we also examined Ser473 phosphorylation of a myristoylated 
Akt/PKB that is constitutively plasma membrane bound (Andjelkovic et al., 1997).  
We found that mTORC2, like mTORC1, is activated in the absence of TSC1-TSC2.  
Our results suggest that mTORC2 is in part responsible for the pathological effects of 
mutations that inactivate TSC1 and TSC2. 
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III.2  Results 
 
 
Figure III-1. 
 
 
 
 
Figure III-1.  Knockdown of TSC1 and TSC2 (TSC1/2) by siRNA stimulates cell 
spreading and Paxillin pY118 phosphorylation. 
(A)  TSC1/2 siRNA prevents cell retraction during serum starvation.  TSCsi293 cells 
were grown for one hour in D-PBS+ supplemented with amino acids in the absence 
of serum, fixed, and stained with rhodamine-phalloidine for visualization of F-actin.  
To induce TSC1/2 siRNA, cells were treated with tetracycline as described in Material 
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and Methods.  Arrowheads indicate lamellipodia-like cell spreading. Thin arrows 
indicate non-spread cell extensions.  Scale bars, 10µm. 
(B)  Quantification of TSCsi293 cell spreading in (A).  100 cells in each of three 
independent experiments were analyzed.  For cells lacking TSC1/2 siRNA (no 
siRNA), 16% of cells were spread and 84% were retracted, whereas TSC1/2 siRNA 
resulted in 73% spread and 27% retracted cells. 
(C)  Tetracycline induced siRNA against TSC1/2 knocked down TSC1 and TSC2 
proteins and stimulated phosphorylation of Paxillin Y118 (Paxillin-pY118).  Western 
analysis of TSCsi293 cells described in (A). 
 
 
III.2.1  TSC1-TSC2 negatively regulates mTORC2-dependent readouts 
 
To investigate if TSC1-TSC2 is upstream of mTORC2, we created a stable, 293T-
REx derived cell line (TSCsi293) expressing TSC1- and TSC2-targeted siRNAs from 
integrated, tetracycline inducible promoters (van de Wetering et al., 2003).  This cell 
line provided a system to examine mTORC2 readouts under conditions of 
reproducible and inducible knockdown of both TSC1 and TSC2.  TSC1 and TSC2 
were efficiently knocked down within 4 days of tetracycline treatment (Figure III-1).  
We first examined the effect of TSC1/2 knockdown on F-actin organization and cell 
spreading in serum starved cells (Figure III-1 A. and B.).  Serum starved conditions 
were chosen because TSC1-TSC2 is normally inactive in serum or growth factor 
treated cells.  Organization of the actin cytoskeleton is a previously characterized 
physiological readout of mTORC2 (Jacinto et al., 2004; Sarbassov et al., 2004).  
Approximately 70% of serum starved cells lacking TSC1/2 (tetracycline treated 
TSCsi293 cells) were spread with F-actin-based lamellipodia-like extensions (Nobes 
and Hall, 1995).  Conversely, less than 20% of serum starved control cells 
(tetracycline untreated TSCsi293 cells) exhibited this behavior.  To investigate further 
the effect of TSC1/2 knockdown on the actin cytoskeleton, we examined Paxillin 
Tyr118 phosphorylation in serum starved cells.  Paxillin is a scaffold protein that 
mediates actin organization in response to growth factors (Brown and Turner, 2004).  
Paxillin Tyr118 phosphorylation, which promotes lamellipodia formation and cell 
spreading, is mTORC2-dependent.  TSC1/2 knockdown stimulated Tyr118 
phosphorylation in serum starved TSCsi293 cells (Figure III-1 C.).    Thus, mTORC2 
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readouts are upregulated in serum starved TSC1/2 knockdown cells, suggesting that 
TSC1-TSC2 inhibits mTORC2 in the absence of serum. 
 
 
Figure III-2. 
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Figure III-2.  mTORC2 mediates the effects of TSC1/2 knockdown. 
(A)  Co-knockdown of mTORC2 (rictor co-siRNA) prevents increased Paxillin Tyr118 
phosphorylation (Paxillin-pY118) due to TSC1/2 knockdown and leads to loss of PKB 
Ser473 phosphorylation (PKB-pS473).  Western analysis of TSCsi293 cells (+/- 
tetracycline induced TSC1/2 siRNA), transiently expressing the indicated co-siRNA.  
The cells were grown for 30 minutes in D-PBS+ supplemented with amino acids in 
the absence of serum before lysis.  
(B)  Co-knockdown of mTORC2 (rictor co-siRNA) prevents cell spreading induced by 
TSC1/2 knockdown.  F-actin and GFP expression in TSCsi293 cells with tetracycline-
induced knockdown of TSC1/2 and expressing the indicated co-siRNA.  The cells 
were grown prior to fixation as in (A).  Arrowheads indicates lamellipodia-like cell 
spreading.  Thin arrows indicate a non-spread cell extension. Scale bars, 10µm. 
(C)   Quantification of TSCsi293 cells in (B).  For each condition, more than 200 GFP 
positive cells from three independent experiments were analyzed.  For cells 
expressing a control co-siRNA, 70% of cells were spread and 30% were retracted, 
whereas upon expression of rictor co-siRNA 24% of the cells were spread and 76% 
of the cells were retracted. 
 
 
III.2.2  mTORC2 mediates effects of TSC1/2 knockdown 
 
To investigate if TSC1/2 indeed inhibits mTORC2, we examined whether mTORC2 
mediates the effects of TSC1/2 knockdown.  To determine the mTORC2-dependence 
of the effects of TSC1/2 knockdown, we combined knockdown of TSC1-TSC2 with 
inhibition of mTORC2, in TSCsi293 cells (Figure III-2).  mTORC2 was inhibited by 
transient transfection of TSCsi293 cells with a pSuper plasmid expressing GFP and 
siRNA (co-siRNA) against the essential mTORC2 component rictor.  Knockdown of 
rictor was confirmed by loss of rictor protein and by loss of Akt/PKB-Ser473 
phosphorylation.  The rictor co-siRNA prevented the stimulation of Paxillin Tyr118 
phosphorylation observed in serum starved TSCsi293 cells upon TSC1/2 knockdown 
(Figure III-2 A.).  Furthermore, the rictor co-siRNA inhibited cell spreading observed 
upon TSC1/2 knockdown.  Less than 25% of TSCsi293 cells with combined 
knockdown of TSC1/2 and rictor (tetracycline treated, GFP expressing cells) 
remained spread, compared to 70% for control cells (Figure III-2 B. and C.).  
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Knockdown of mTORC1 with co-siRNA against the essential mTORC1 component 
raptor had no effect on Paxillin Tyr118 phosphorylation or cell spreading (data not 
shown). Thus, inhibition of mTORC2 prevented the effects observed upon TSC1/2 
knockdown, confirming that TSC1-TSC2 inhibits mTORC2. 
 
 
III.2.3  TSC1-TSC2 inhibits mTORC2 activity towards plasma membrane bound 
Akt/PKB 
 
Yang et al. (Yang et al., 2006), using Akt/PKB Ser473 phosphorylation as a readout 
for mTORC2 activity, previously suggested that TSC1-TSC2 activates mTORC2 (see 
Introduction), whereas we find that TSC1-TSC2 inhibits mTORC2 (see above).  To 
investigate this apparent contradiction, we examined the effect of TSC1/2 knockdown 
on Ser473 phosphorylation of myristoylated, and thus constitutively plasma 
membrane bound, Akt/PKB (myr-Akt/PKB) (Andjelkovic et al., 1997). This allowed us 
to determine whether the effect of TSC1/2 knockdown on Akt-PKB Ser473 
phosphorylation is due to lack of Akt/PKB localization or, alternatively, due to lack of 
mTORC2 kinase activity.  myr-Akt/PKB Ser473 phosphorylation increased in serum 
starved TSCsi293 cells upon knockdown of TSC1/2 (Figure III-3).  Inhibition of 
mTORC2 with rictor co-siRNA prevented myr-Akt/PKB Ser473 phosphorylation 
(Figure III-3), confirming that mTORC2 mediated the phosphorylation of myr-Akt/PKB 
Ser473.  Thus, mTORC2 is able to phosphorylate Akt/PKB in the absence of TSC1-
TSC2 if Akt/PKB is at the plasma membrane. Apparently, Akt/PKB that is not plasma 
membrane bound is not accessible for phosphorylation by mTORC2.  These findings 
suggest that Yang et al. (Yang et al., 2006) failed to detect mTORC2 activity in 
TSC1/2 mutant cells due to an indirect effect on Akt/PKB localization rather than to 
an effect on mTORC2 activity itself.  These findings also suggest that TSC1-TSC2 is 
not required to activate mTORC2.  Indeed, the observation that mTORC2-dependent 
myr-Akt/PKB Ser473 phosphorylation, like Paxillin Tyr118 phosphorylation and cell 
spreading, increased upon TSC1/2 knockdown provides further evidence that TSC1-
TSC2 inhibits mTORC2. 
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Figure III-3. 
 
 
 
Figure III-3.   Knockdown of TSC1/2 increases mTORC2-dependent phosphorylation 
of membrane bound Akt/PKB (HA-myr-PKB).  Ser473 phosphorylated (PKB-pS473) 
and total (HA) HA-myr-PKB immunoprecipitated with anti-HA (IP: HA) from TSCsi293 
cells induced (+) or non-induced (-) for TSC1/2 siRNA, and transiently expressing the 
indicated constructs. Indicated proteins were probed in total lysate.  The cells were 
grown for 30 minutes in D-PBS+ supplemented with amino acids in the absence of 
serum before lysis.  
 
 
III.2.4  Overexpression of Rheb activates mTORC1 but not mTORC2  
 
TSC1-TSC2, a GTPase activating complex, inhibits mTORC1 via downregulation of 
the small GTPase Rheb.  To determine whether TSC1-TSC2 inhibits mTORC2 also 
via inhibition of Rheb, we investigated if overexpression of Rheb activates mTORC2.  
The mTORC2 readout Paxillin Tyr118 phosphorylation was examined in starved cells 
overexpressing Rheb.  As a positive control for Rheb function, we also examined the 
mTORC1 readout S6K Thr389 phosphorylation.  Overexpression of Rheb failed to 
stimulate Paxillin Tyr118 phosphorylation.  In contrast, Rheb overexpression 
stimulated S6K Thr389 phosphorylation (Figure III-4 A.).  Similar results (data not 
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shown) were obtained with overexpression of RhebL1, a functional homolog of Rheb 
(Tee et al., 2005).  Thus, Rheb and RhebL1 activate mTORC1 but not mTORC2.  
This is consistent with the observation of Yang et al. (Yang et al., 2006) that Rheb 
knockdown, although inhibiting TORC1, does not prevent activation of TORC2.  
Taken together, the above findings suggest that TSC1-TSC2 inhibition of mTORC2 is 
independent of Rheb.  TSC1-TSC2 may inhibit mTORC2 via another, unknown small 
GTPase. 
 
 
Figure III-4. 
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Figure III-4.  mTORC1 and mTORC2 respond differently to amino acids and Rheb 
overexpression but similarly to serum and insulin. 
 (A) Rheb overexpression stimulates phosphorylation of S6K Thr389 (S6K-pT389) 
but not of Paxillin Tyr118 (Paxillin-pY118).  Western analysis of HEK293T cells 
expressing the indicated constructs and grown in D-PBS+ lacking amino acids and 
serum for 30 minutes before lysis.  
(B) Amino acids stimulate phosphorylation of S6K Thr389 (S6K-pT389) but not of 
Paxillin Tyr118 (Paxillin-pY118).  Western analysis of HEK293T cells deprived of 
serum overnight (17 hours) and either grown unchanged in D-MEM or grown in D-
PBS+ with the indicated supplements for 30 minutes before lysis.  Amino acids 
strongly induced only S6K-pT389, whereas insulin and serum stimulated PKB Ser473 
(PKB-pS473), Paxillin-pY118, and S6K-pT389. 
 
 
III.2.5  Amino acids activate mTORC1 but not mTORC2 
 
The apparently different requirement for Rheb in the activation of mTORC1 and 
mTORC2 suggests that the two mTOR complexes may respond differently to 
extracellular stimuli.  To investigate this possibility, we compared the ability of amino 
acids, insulin and serum to stimulate mTORC1- and mTORC2-dependent readouts in 
HEK293T cells (Figure III-4 B.). Amino acids, insulin and serum are well-
characterized extracellular stimuli for mTORC1.  We found that amino acids 
stimulated phosphorylation of the mTORC1 effector S6K (Thr389) but not of the 
mTORC2 effector Paxillin (Tyr118).  Insulin stimulated phosphorylation of both S6K 
Thr389 and Paxillin Tyr118, although the stimulation of S6K Thr389 phosphorylation 
was evident only in the presence of amino acids.  Serum stimulated phosphorylation 
of both Paxillin Tyr118 and S6K Thr389.  As a control, we also examined 
phosphorylation of Akt/PKB Ser473.  As expected, insulin and serum but not amino 
acids stimulated phosphorylation of Ser473.   These findings suggest that, unlike 
mTORC1, mTORC2 does not respond to amino acids.  Furthermore, the two 
mTORCs respond differently to amino acids in the same way they respond differently 
to Rheb (see above).  This correlation suggests that amino acids may impinge on 
mTORC1 via Rheb.  In addition, as both mTORCs are inhibited by TSC1-TSC2, yet 
only mTORC1 responds to amino acids, the TSC complex appears not to play a role 
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in signaling amino acid availability.  Long et al. (Long et al., 2005b) have reported 
previously that the GTP loading of Rheb is independent of amino acids, providing 
further evidence that amino acids do not signal via the TSC complex. 
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III.3  Discussion 
 
We have presented evidence that mTORC2, like mTORC1, is negatively regulated by 
TSC1-TSC2.  This conclusion appears to contradict Yang et al. (Yang et al., 2006) 
who suggested that mTORC2, unlike mTORC1, is activated by TSC1-TSC2.  This 
apparent contradiction can be explained by the negative feedback loop in the insulin 
pathway and the choice of mTORC2 readouts used to study mTORC2 activity.  Like 
Yang et al. (Yang et al., 2006), we observed that loss of TSC1-TSC2 reduced 
Akt/PKB Ser473 phosphorylation (Figure III-2 A.).  However, we also found that loss 
of TSC1-TSC2 stimulated mTORC2-dependent phosphorylation of Paxillin and 
constitutively membrane bound myr-Akt/PKB.  Thus, loss of TSC1-TSC2 activates 
mTORC2 but prevents membrane localization of Akt/PKB.  In other words, reduced 
Akt/PKB Ser473 phosphorylation in TSC mutant cells is due to loss of Akt/PKB 
recruitment to the membrane rather than to loss of mTORC2 activity.   Loss of TSC1-
TSC2 prevents Akt/PKB recruitment, and thereby accessibility to mTORC2, by 
triggering the negative feedback loop in the PI3K/insulin pathway.  Further support 
for this explanation is provided by the observation that inhibition of the negative 
feedback loop (with rapamycin) in insulin treated TSC mutant cells restores Ser473 
phosphorylation (Harrington et al., 2004; Yang et al., 2006).  Similarly, a PTEN 
mutation restores Ser473 phosphorylation in TSC mutant cells (Ma et al., 2005b).  
The negative feedback loop prevents membrane recruitment of Akt/PKB by inhibiting 
PI3K, which in turn causes reduced PIP3 levels in the plasma membrane.  PIP3 
normally binds the PH domain in Akt/PKB and thereby recruits Akt/PKB to the plasma 
membrane (Fayard et al., 2005). 
  
We also found that mTORC2 is stimulated by insulin and serum, but not by 
amino acids.  This creates a conundrum when one considers that mTORC2 activates 
Akt/PKB and that Akt/PKB is required to inhibit TSC1-TSC2 upstream of mTORC2.  
How does insulin inhibit TSC1-TSC2 and thereby stimulate mTORC2 if mTORC2 is 
first needed to phosphorylate (Ser473) and activate Akt/PKB?  The answer to this 
question may be found in the observation that knockdown of mTORC2 does not 
affect mTORC1-dependent S6K activation (Jacinto et al., 2004; Sarbassov et al., 
2005b).  This observation suggests that mTORC2-mediated phosphorylation of 
Akt/PKB is not required to activate Akt/PKB towards TSC1-TSC2.  PDK1-mediated 
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phosphorylation of Thr308 in the activation loop of Akt/PKB may be sufficient to 
activate Akt/PKB towards TSC1-TSC2, but subsequent phosphorylation of Ser473 in 
the hydrophobic motif of Akt/PKB by mTORC2 may be necessary to activate Akt/PKB 
towards other substrates such as FoxO (see model in Figure III-5).  This model is 
also supported by recent findings of Jacinto et al. (Jacinto et al., 2006) showing that 
an mTORC2 knockout eliminates Akt/PKB Ser473 phoshorylation but affects 
signaling only to a subset of Akt/PKB substrates.  In particular, they show that 
mTORC2-dependent phosphoryaltion of Ser473 is required for signaling to FoxO but 
not for signaling to TSC1-TSC2 or GSK3.  Thus, Ser473 phosphorylation determines 
Akt/PKB substrate specificity rather than absolute activity, as shown in the model of 
Figure III-5.  
 
We also observed that overexpression of Rheb activated mTORC1 but not 
mTORC2.  In agreement, Yang et al. (Yang et al., 2006) have reported that 
knockdown of Rheb prevents activation of TORC1 but not of TORC2.  Thus, Rheb is 
an upstream regulator of mTORC1 but not of mTORC2 (Figure III-5).  This correlates 
with our additional observation that amino acids, although able to activate mTORC1, 
do not activate mTORC2.  Furthermore, recent results have suggested that amino 
acids activate mTORC1 via Rheb independently of TSC1-TSC2. The binding of Rheb 
to mTORC1 is regulated by amino acid availability but GTP charging of Rheb is 
independent of amino acids (Long et al., 2005b).  In addition, TSC deficient cells still 
respond to amino acid starvation (Smith et al., 2005) (data not shown).  Together, 
these findings suggest that TSC1-TSC2 inhibits mTORC2 by acting on a protein 
other than Rheb.  This other protein, possibly a GTPase, would be insensitive to 
amino acids. 
 
Mutations that inactivate TSC1 or TSC2 result in a variety of diseases 
characterized by cell overgrowth, including Tuberous Sclerosis Complex (TSC) and 
Lymphangioleiomyomatosis (LAM). Inhibition of mTORC1 with rapamycin analogs is 
currently being considered as a strategy in the treatment of TSC and LAM (Johnson, 
2006; Kwiatkowski and Manning, 2005).  Interestingly, deregulation of the actin 
cytoskeleton via Rac1 and RhoA appears to contribute to the metastatic invasiveness 
of angiomyolipoma smooth muscle cells in LAM patients (Astrinidis et al., 2002; 
Goncharova et al., 2006a; Henske, 2003).  We found that a TSC1/2 deficiency 
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stimulates mTORC2-dependent actin polymerization and Paxillin Tyr118 
phosphorylation.  Paxillin Tyr118 phosphorylation promotes cell migration and 
regulates Rac1 and RhoA (Brown and Turner, 2004).  These findings suggest that 
mTORC2 may contribute to the invasiveness of TSC and LAM cells. Thus, effective 
intervention in the treatment of TSC, LAM and related diseases may require inhibition 
of both mTORC1 and rapamycin-insensitive mTORC2. 
 
 
Figure III-5. 
 
 
 
 
Figure III-5.   Model of mTOR signalling network showing negative regulation of 
mTORC2 by TSC1-TSC2.   
TSC1-TSC2 inhibits mTORC2 independently of Rheb.  TSC1-TSC2 inhibits mTORC1 
via inactivation of Rheb.  mTORC2 phoshorylates Ser473 (pS473) in the hydrophobic 
motif of Akt/PKB (PKB).  PDK1 phosphorylates Thr308 (not indicated) in the 
activation loop of Akt/PKB.  Ser473 phosphorylation determines the substrate 
specificity of Akt/PKB.  mTORC1 activates S6K and thereby induces feedback 
inhibition of the insulin pathway upstream of PI3K.  Inhibition of PI3K by the negative 
feedback loop prevents membrane recruitment of PKB and PDK1.  In TSC deficient 
cells, hyperactive mTORC1 inhibits membrane translocation of PKB, leaving PKB 
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inaccessible to activated mTORC2.  Amino acids stimulate mTORC1 (but not 
mTORC2) via Rheb.  
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IV. Additional Results 
 
 
IV.1.1  Tetracycline treatment of 293T-REx cells does not affect mTOR 
signaling. 
 
To test if tetracycline treatment interfered with mTOR signaling we examined the 
effects of tetracycline treatment on readouts for mTORC1 and mTORC2 in 293T-REx 
cells.  We found that phosphorylation of Paxillin Tyr118, Akt/PKB Ser473 or S6K 
Thr389 did not change due to the tetracycline treatment that we used in TSCsi293 
cells to induce knockdown of TSC1/2 (Figure IV-1).  This result ensured that the 
tetracycline inducible system was suitable to study the mTOR pathway. 
 
 
Figure IV-1. 
 
 
 
Figure IV-1.  Control experiment for tetracycline treatment in 293T-REx cells. 
Tetracycline treatment for 72 hours did not affect phosphorylation of Paxillin Tyr118 
(pY118), Akt/PKB Ser473 (pS473) or S6K Thr389 (pT389). Western analysis of 
293T-REx cells, either treated with tetracycline (4 µg/ml) for 4 days or not and either 
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stimulated or starved in D-PBS+ supplemented as indicated for 30 minutes before 
lysis. 
 
 
IV.1.2  Effects of non-targeting siRNA in 293T-REx on mTOR signaling. 
 
To test if expression of siRNA exhibited off-target effects on mTOR signaling we 
examined readouts for mTORC1 and mTORC2 in 293T-REx cells that expressed 
non-targeted control siRNA.  We found that phosphorylation of Paxillin Tyr118, 
Akt/PKB Ser473 or S6K Thr389 was not affected by expression of control siRNA 
(Figure IV-2).  This result ensured that using siRNA was suitable to study mTOR 
signaling. 
 
 
Figure IV-2. 
 
 
 
Figure IV-2.  Control experiment for non-targeting siRNA in 293T-REx cells. 
Transient expression of non-targeted control siRNA did not affect phosphorylation of 
Paxillin Tyr118 (pY118), Akt/PKB Ser473 (pS473) or S6K Thr389 (pT389).  Western 
analysis of 293T-REx cells either transfected or not with control siRNA.  The cells 
were grown for 60 minutes in D-PBS+ supplemented with amino acids before lysis. 
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Figure IV-3. 
 
 
 
Figure IV-3.  RhebL1 overexpression stimulates phosphorylation of S6K Thr389 
(pT389) but not of Paxillin Tyr118 (pY118) or Akt/PKB Ser473 (pS473).  
Western analysis of TSCsi293 cells, induced for TSC1/2 knockdown or not, that 
transiently expressed either GFP or RhebL1 tagged with GST or Flag.  The cells 
were grown in D-PBS+ supplemented with serum for 30 minutes before lysis. 
 
 
IV.1.3  RhebL1 activates mTORC1 but not mTORC2. 
 
The GTPase activating hetero-complex TSC1-TSC2 inhibits mTORC1 via 
downregulation of the small GTPase Rheb.  We found that Rheb did not mediate the 
stimulation of mTORC2-dependent phosphorylation of Paxillin Tyr118 upon TSC1/2 
knockdown (see III.2.4).  Alternatively, it was possible that RhebL1 (Tee et al., 2005), 
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a functional homolog of Rheb, mediated mTORC2 activation upon knockdown of 
TSC1/2.  To determine whether TSC1-TSC2 inhibits mTORC2 via inhibition of 
RhebL1, we investigated if overexpression of RhebL1 stimulated phosphorylation of 
Paxillin Tyr118.  As a positive control for RhebL1 function, we also examined the 
mTORC1 readout S6K Thr389 phosphorylation.  Overexpression of RhebL1, like 
overexpression of Rheb, failed to stimulate Paxillin Tyr118 phosphorylation (Figure 
IV-3).  In contrast, RhebL1 overexpression stimulated S6K Thr389 phosphorylation.  
Thus, RhebL1, just like Rheb, activates mTORC1 but not mTORC2, suggesting that 
TSC1-TSC2 inhibits mTORC2 independently of Rheb and RhebL1.  This finding adds 
to the conclusion that TSC1-TSC2 inhibits mTORC2 by a mechanism that is different 
from inhibition of mTORC1. 
 
 
IV.1.4  Phosphorylation of Paxillin Tyr118 and S6K Thr389 peaks after 30 
minutes of serum stimulation. 
 
To determine if serum stimulates phosphorylation of mTOR readouts in TSCsi293 
cells in a time dependent manner, we performed a time course for serum stimulation.  
TSCsi293 cells were stimulated with 10% serum for either 0, 15, 30, 45, 60 or 90 
minutes to examine phosphorylation of Paxillin Tyr118, Akt/PKB Ser473 and S6K 
Thr389.  We found that Paxillin Tyr118 phosphorylation peaked after 30 minutes of 
serum stimulation (Figure IV-4).  Phosphorylation of Paxillin decreased again 
between 30 and 45 minutes after stimulation, and came down to the initial level at 90 
minutes post stimulation.  We found similar kinetics for serum stimulated Paxillin 
Tyr118 phosphorylation in TSCsi293 cells if TSC1/2 were knocked down, which 
suggested the existence of additional regulatory mechanisms for Paxillin 
phosphorylation in parallel to hyperactivated mTORC2.  Phosphorylation of Akt/PKB 
Ser473 did not change upon serum stimulation. S6K Thr389 phosphorylation 
increased upon serum stimulation and peaked between 15 and 30 minutes after the 
stimulation.  S6K Thr389 phosphorylation also decreased between 30 and 45 
minutes after serum stimulation and came back to the initial level at 90 minutes post 
stimulation.  We cannot exclude that increased S6K phosphorylation upon serum 
stimulation was due to amino acids present in the serum.  In summary, serum 
stimulation induces a peak in phosphorylation of Paxillin Tyr118 and S6K Thr389 
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after around 30 minutes.  For this reason, we chose 30 minutes as the appropriate 
period to study serum stimulation in TSCsi293 cells. 
 
 
Figure IV-4. 
 
 
 
 
Figure IV-4.  Time course for serum stimulation of TSCsi293 cells. 
Phosphorylation of Paxillin Tyr118 (pY118), AKT/PKB Ser473 (pS473) and S6K 
Thr389 (pT389) at indicated times in minutes (min) after stimulation with 10 % serum.  
Western analysis of TSCsi293 cells either induced for TSC1/2 knockdown or not.  
The cells were grown for the according times in D-PBS+ supplemented with serum 
before lysis. 
 
 
IV.1.5  Between 5-10 % of serum is required for maximal serum stimulation of 
Paxillin Tyr118 phosphorylation in TSCsi293 cells.  
 
To determine the optimal serum concentration needed for effective stimulation of 
mTOR readouts in TSCsi293 cells, we performed a serum concentration gradient for 
30 minutes of serum stimulation and examined phosphorylation of Paxillin, PKB and 
S6K.  Between 5-10 % of serum induced maximal phosphorylation of Paxillin Tyr118 
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in TSCsi293 cells either induced for TSC1/2 knockdown or not (Figure IV-5).  
Akt/PKB Ser473 phosphorylation did not change upon stimulation with any of the 
tested serum concentrations.  S6K Thr389 phosphorylation was maximal between 5-
10 % of serum.  Thus, 30 minutes of serum stimulation require 5-10 % of serum for 
effective stimulation of Paxillin Tyr118 phosphorylation.  For this reason, we decided 
to stimulate TSCsi293 cells with 10 % serum in our experiments. 
 
 
Figure IV-5. 
 
 
 
 
Figure IV-5.  Serum gradient for stimulation of TSCsi293 cells. 
Phosphorylation of the mTOR readouts Paxillin Tyr118 (Y118), AKT/PKB Ser473 
(S473) and S6K Thr389 (T389) after 30 minutes of stimulation with serum at 
indicated concentrations.  Western analysis of TSCsi293 cells either induced for 
TSC1/2 knockdown or not.  The cells were grown for 30 minutes in D-PBS+ with the 
indicated concentrations of serum before lysis. 
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IV.1.6  Serum stimulates mTORC2-dependent Akt/PKB Ser473 phosphorylation. 
 
As serum did not stimulate phosphorylation of Akt/PKB Ser473 in TSCsi293 cells 
(Figures IV-4 and IV-5), we further analysed the effects of overnight serum 
deprivation and serum re-stimulation on phosphorylation of mTOR readouts in these 
cells.  We examined the effects of serum deprivation and re-stimulation because 
similar conditions were chosen in initial studies on Akt/PKB activation by growth 
factors (Andjelkovic et al., 1997).  TSCsi293 cells were serum deprived for 17 hours 
or not and the deprived cells were then re-stimulated for 30 minutes with serum or 
not. Phosphorylation of Ser473 in Akt/PKB decreased upon serum deprivation 
(Figure IV-6), suggesting that the presence of serum maintains Akt/PKB activity.  
Serum re-stimulation induced phosphorylation of Akt/PKB Ser473 to similar levels as 
observed in non-deprived cells, which further shows the positive serum effect on 
Akt/PKB activation.  We observed similar kinetics for Akt/PKB activation in TSCsi293 
cells having knocked down TSC1/2 and can therefore conclude that TSC1-TSC2 
inhibition by siRNA does not induce a negative feedback inhibition towards serum 
sensing pathways in TSCsi293 cells.  Paxillin Tyr118 phosphorylation increased upon 
serum re-stimulation also if TSC1/2 were knocked down, which further suggests that 
Paxillin phosphorylation is regulated by other signals in parallel to the regulation by 
TSC1-TSC2. Phosphorylation of S6K Thr389 increased upon TSC1/2 knockdown. 
mTORC1-dependent  phosphorylation of Ser235/Ser236 in S6 (Pende et al., 2004) 
increased after changing the medium, which was probably caused by amino acids in 
the medium (DMEM).  S6 Ser235/Ser236 phosphorylation additionally increased 
upon TSC1/2 knockdown.  Furthermore, we found that serum strongly induced 
phosphorylation of ERK1/2 Thr202/Tyr204 (see also Figures IV-11 and IV-14).  Thus, 
serum not only stimulates phosphorylation of Paxillin Tyr118 but also maintains 
phosphorylation of Akt/PKB Ser473 and even induces Akt/PKB Ser473 
phosphorylation in serum deprived cells.  The observation that TSCsi293 cells are 
still sensitive to serum deprivation and restimulation suggests that more regulators 
besides TSC1-TSC2 account for phosphorylation of Akt/PKB and Paxillin.  The 
stimulating effect of serum on these mTORC2 readouts also suggests that mTORC2 
is activated by serum.  Serum may therefore either stimulate mTORC2 activity, or 
stimulate co-factors that are required for mTORC2-dependent signaling, or both. 
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Figure IV-6. 
 
 
 
Figure IV-6.  Serum starvation and serum re-stimulation of TSCsi293 cells. 
Phosphorylation of Paxillin Tyr118 (pY118), Akt/PKB Ser473 (pS473), S6K Thr389 
(pT389), S6 Ser235/Ser236 (pS235/S236) and ERK1/2 Thr202/Tyr204 (pT202/Y204) 
were detected after overnight serum deprivation and serum re-stimulation.  Western 
analysis of TSCsi293 cells either induced for TSC1/2 knockdown or not.  The cells 
were either serum deprived for 17 hours in DMEM (including fresh amino acids) 
without serum or not and then either re-stimulated with serum for 30 minutes in 
DMEM (including fresh amino acids) supplemented with serum or not before lysis. 
 
 
IV.1.7  Insulin stimulation of mTOR readouts reaches a maximum after 30 
minutes. 
 
To determine if insulin stimulation of mTOR readouts is time dependent in TSCsi293 
cells, we performed a time course for stimulation with 100 nM insulin and examined 
the phosphorylation of Paxillin Tyr118, Akt/PKB Ser473 and S6K Thr389.  If cells 
were not pre-starved for serum, we detected no strong increase in Paxillin 
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phosphorylation by insulin stimulation (Figures IV-7, IV-10 and IV-11).  Insulin 
induced Akt/PKB Ser473 phosphorylation already after 15 minutes, resulting in a 
stable signal over the examined period, independently of TSC1/2 knockdown (Figure 
IV-7), which suggested that knockdown of TSC1/2 did not inhibit the insulin response 
in TSCsi293 cells.  Phosphorylation of S6K1 Thr389 was only weakly detectable if we 
knocked down TSC1/2 in TSCsi293 cells, which is a result from the absence of 
amino acids (IV-7).  However, in TSC1/2 knockdown we found S6K Thr389 
phosphorylation to peak after 30 minutes of insulin stimulation.  We found similar 
kinetics for Akt/PKB Ser473 phosphorylation in TSCsi293 cells when combining 
insulin and amino acid stimulation (Figure IV-10).  As we found a stable induction 
over time from insulin stimulation towards Akt/PKB activation while for S6K activation 
we observed a peak after 30 minutes of insulin stimulation, we decided to study 
insulin effects after 30 minutes of stimulation.  
 
 
Figure IV-7. 
 
 
 
 
Figure IV-7.  Time course for insulin stimulation of TSCsi293 cells. 
Phosphorylation of the mTOR readouts Paxillin Tyr118 (pY118), AKT/PKB Ser473 
(pS473) and S6K Thr389 (pT389) at indicated times in minutes (min.) after 
stimulation with 100 nM insulin.  Western analysis of TSCsi293 cells either induced 
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for TSC1/2 knockdown or not.  The cells were grown for the according times in D-
PBS+ supplemented with insulin before lysis. 
 
 
IV.1.8  Maximal insulin stimulation of mTORC2 readouts requires 100 nM 
insulin. 
 
To determine an optimal insulin concentration for effective stimulation of mTORC2-
dependent phosphorylation of Paxillin Tyr118 and Akt/PKB Ser473 in serum starved 
TSCsi293 cells, we performed a concentration gradient for 30 minutes of insulin 
stimulation and examined phosphorylation of Paxillin and PKB.  Phosphorylation of 
Paxillin Tyr118 and Akt/PKB Ser473 in serum starved TSCsi293 cells was maximal 
upon 100 nM insulin stimulation (Figure IV-8).  We observed similar kinetics when the 
cells had been knocked down for TSC1/2, again showing that TSC1/2 knockdown did 
not inhibit insulin signaling.  Thus, maximal insulin stimulation of mTORC2 readouts 
requires 100 nM insulin.  For this reason, we stimulated TSCsi293 cells with 100 nM 
of insulin.  
 
 
Figure IV-8. 
 
 
 
 
Figure IV-8. Insulin gradient for stimulation of serum deprived TSCsi293 cells. 
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Phosphorylation of Paxillin Tyr118 (pY118) and AKT/PKB Ser473 (pS473) were 
detected upon stimulation for 30 minutes with the indicated insulin concentrations.  
Western analysis of TSCsi293 cells either induced for TSC1/2 knockdown or not.  
The cells were serum deprived for 17 hours in DMEM without serum and grown in D-
PBS+ supplemented with the according concentrations of insulin before lysis. 
 
 
IV.1.9  S6K Thr389 phosphorylation peaks after 30 minutes of amino acid 
stimulation. 
 
To determine if amino acids stimulate phosphorylation of mTOR readouts in 
TSCsi293 cells in a time dependent manner, we performed a time course for amino 
acid stimulation and examined migration of 4E-BP1 and phosphorylation of S6K 
Thr389, Paxillin Tyr118 and Akt/PKB Ser473.  Phosphorylation of the mTORC1 
readout S6K Thr389 peaked after 30 minutes of stimulation with amino acids (Figure 
IV-9).  Between 45 and 60 minutes post stimulation the phosphorylation of S6K 
Thr389 declined again.  We observed similar kinetics when the cells were knocked 
down for TSC1/2 or when insulin was present in addition (Figure IV-10).  This finding 
suggests that the TSC deficiency in these cells does not affect the response to amino 
acid stimulation and provides new evidence for a TSC1-TSC2-independent signal 
transduction of amino acid stimulation towards mTORC1.  Migration speed of 4E-BP1 
slowed down after 30 minutes of amino acid stimulation, reflecting complete 
phosphorylation by mTORC1.  60 minutes post stimulation we found that 4E-BP1 
migrated again faster and together with the concomitant decline of S6K Thr389 
phosphorylation after an initial peak, this finding suggests that a negative feedback 
regulatory mechanism limits hyperactivation of mTORC1 after acute amino acid 
stimulation.  The phosphorylation of the mTORC2 readouts Paxillin Tyr118 and 
Akt/PKB Ser473 did not change upon amino acid stimulation.  In summary, amino 
acid stimulation induced a peak in S6K Thr389 phosphorylation and 4E-BP1 
phosphorylation after 30 minutes of stimulation.  For this reason, we chose 30 
minutes as the appropriate time period to study amino acid stimulation in TSCsi293 
cells. 
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Figure IV-9. 
 
 
 
 
Figure IV-9.  Time course for amino acid stimulation of TSCsi293 cells. 
Phosphorylation of the mTOR readouts Paxillin Tyr118 (pY118), AKT/PKB Ser473 
(pS473) and S6K Thr389 (pT389) and the migration pattern of 4E-BP1 were detected 
at indicated times in minutes (min.) after stimulation with amino acids.  Western 
analysis of TSCsi293 cells either induced for TSC1/2 knockdown or not.  The cells 
were grown for the according times in D-PBS+ supplemented with amino acids (1x 
MEM essential and non- essential amino acids mix) before lysis. 
 
 
IV.1.10  Combined stimulation of amino acids and insulin. 
 
Combined stimulation with amino acids and insulin reflected the additive signaling 
response of the two single stimuli on mTOR readouts (compare Figures IV-7 and IV-
9). 
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Figure IV-10. 
 
 
 
 
Figure IV-10.  Time course for combined amino acid and insulin stimulation of 
TSCsi293 cells. 
Migration of 4E-BP1 and phosphorylation of the mTOR readouts Paxillin Tyr118 
(pY118), AKT/PKB Ser473 (pS473) and S6K Thr389 (pT389) was detected at 
indicated times in minutes (min.) after stimulation with insulin and amino acids.  
Western analysis of TSCsi293 cells either induced for TSC1/2 knockdown or not.  
The cells were serum deprived for 17 hours in DMEM without serum and grown for 
different times in D-PBS+ supplemented with amino acids (1x MEM essential and 
non-essential amino acids mix) and 100 nM insulin before lysis. 
 
 
IV.1.11  Distinct extracellular stimuli or TSC1/2 knockdown exert different 
effects on phosphorylation of Paxillin Tyr118, PKB Ser473 and S6K Thr389. 
 
We found that stimulation with amino acids, serum or insulin induced phosphorylation 
of the mTORC1 readout S6K Thr389, whereas only serum and insulin but not amino 
acids stimulated phosphorylation of the mTORC2 readouts Paxillin Tyr118 and 
Akt/PKB Ser473 in serum-deprived HEK293T cells (see III.2.5).  To determine the 
role of TSC1-TSC2 in the signal transduction from these extracellular stimuli towards 
phosphorylation of mTOR readouts, we examined the effects of TSC1/2 knockdown 
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on phosphorylation of Paxillin, PKB and S6K in TSCsi293 cells that were either 
stimulated with or starved for amino acids, serum, insulin or a combination of these.  
Amino acids turned out to be the predominant stimulus for inducing phosphorylation 
of S6K Thr389 in TSCsi293 cells (Figure IV-11).  We found only one condition, in 
which we could detect a slight increase in S6K Thr389 phosphorylation upon TSC1/2 
knockdown that was in the combination of amino acid starvation with insulin 
stimulation, again illustrating only a very mild effect from TSC1/2 knockdown towards 
mTORC1 activation in the TSCsi293 cell line.  TSC1/2 knockdown did not prevent 
dephosphorylation of S6K Thr389 upon amino acid starvation, nor did it prevent the 
responsiveness to amino acid stimulation, illustrating further that amino acids do not 
primarily signal via TSC1-TSC2.  
 
Independently of TSC1/2 knockdown, mTORC2-dependent phosphorylation of 
Akt/PKB Ser473 increased upon stimulation with insulin but not upon serum if the 
TSCsi293 cells had not been serum-starved prior stimulation (Figure IV-11; compare 
also Figures IV-4, IV-6 and IV-7).  TSC1/2 knockdown did not prevent 
phosphorylation of Akt/PKB Ser473 upon insulin stimulation in TSCsi293 cells, 
showing once more that TSC1/2 knockdown did not markedly induce feedback 
inhibition towards the insulin pathway in our system.  This was consistent with the 
mild effects from TSC1/2 knockdown on S6K activation.  It appears likely that 
endogenous Rheb levels are very low in comparison to other cells, in which S6K is 
strongly activated upon TSC1 or TSC2 deficiency.  This assumption would also 
match with the very faint signal that we received for endogenous levels of Rheb in 
TSCsi293 cells (data not shown).  To determine further if TSC1/2 knockdown did not 
induce negative feedback inhibition of the insulin pathway, we also examined PDK1-
dependent phosphorylation of Akt/PKB Thr308.  Efficient phosphorylation of Akt/PKB 
Thr308 requires membrane recruitment of both, PDK1 and Akt/PKB, via PI3K-
dependent PIP3 generation.  Akt/PKB Ser473 phosphorylation did not change upon 
TSC1/2 knockdown in TSCsi293 cells that were stimulated with growth factors, 
whereas TSC1/2 knockdown lead to reduced phosphorylation of Akt/PKB Thr308 in 
TSCsi293 cells that were starved for growth factors (Figure IV-11).  This reduction of 
Akt/PKB Thr308 phosphorylation in TSCsi293 cells upon TSC1/2 knockdown 
suggests that less PDK1 and Akt/PKB translocated to the membrane. Nevertheless, 
we found that Akt/PKB Ser473 phosphorylation was not reduced upon TSC1/2 
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knockdown in growth factor starved cells. The reduction of only Thr308 
phosphorylation but not Ser473 phosphorylation upon TSC1/2 knockdown possibly 
reflects increased mTORC2 activity. Seen it this way, the shifted ratio between 
Ser473 and Thr308 Akt/PKB phosphorylation towards mTORC2-dependent Ser473 
upon TSC knockdown matches with our previous finding that mTORC2-dependent 
phosphorylation of membrane located Akt/PKB Ser473 (myr-AktPKB Ser473) 
increases upon knockdown of TSC1/2 and provides further evidence that TSC1-
TSC2 negatively regulates mTORC2 activity towards Akt/PKB.  
 
Phosphorylation of Paxillin Tyr118 increased upon TSC1/2 knockdown (Figure 
IV-11).  Serum strongly stimulated Paxillin Tyr118 phosphorylation whereas insulin 
did not if TSCsi293 cells were not serum-pre-deprived over night.  Surprisingly, 
serum and insulin affected phosphorylation of the mTORC2 readouts Paxillin and 
Akt/PKB in different ways.  Both stimuli induced mTORC2-dependent 
phosphorylation of Paxillin and Akt/PKB in TSCsi293 cells that were deprived for 
serum overnight (see III.2.5).  However, if the cells were not serum deprived prior 
stimulation, we found that serum did not induce phosphorylation of PKB Ser473 while 
efficiently inducing phosphorylation of Paxillin Tyr118, whereas insulin on the other 
hand did not induce phosphorylation of Paxillin while efficiently inducing PKB 
phosphorylation (Figure IV-11).  This difference between serum and insulin 
stimulation might result from stronger stimulation of PI3K-dependent PIP3 levels by 
insulin in comparison to serum.  Serum on the other hand might stimulate a different 
co-factor stronger than insulin does to allow efficient mTORC2-dependent Paxillin 
phosphorylation.  Putative co-activators for efficient Paxillin phosphorylation could be 
the MAP kinases ERK1 and ERK2 because ERK1/2 activation, like Akt/PKB 
activation, inhibits TSC1-TSC2 to activate mTOR.  ERK1/2, like Akt/PKB inactivates 
TSC1-TSC2 by direct phosphorylation of TSC2 on specific residues (Ma et al., 
2005a).  Furthermore, serum stimulation activates ERK1/2 and ERK1/2 is a known 
modulator of Paxillin phosphorylation (Brown and Turner, 2004).  To determine 
further if ERK1/2 are indeed co-activators for mTORC2-dependent Paxillin Tyr118 
phosphorylation we took a closer look at ERK1/2 activity in our experiment.  ERK1/2 
activation can be monitored by MEK1/2-dependent phosphorylation of ERK1/2 on 
Thr202/Tyr204.  As for Paxillin Tyr118, serum greatly stimulated phosphorylation of 
ERK1/2 on Thr202/Tyr204, whereas insulin did not (Figure IV-11). This result argued 
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in favour of the idea that ERK1/2 could serve as a co-activator for efficient 
phosphorylation of Paxillin Tyr118 upon serum stimulation (compare also Figure IV-
6).   
 
To summarize, we found further evidence that amino acids signal 
independently of TSC1-TSC2 towards mTORC1.  We also found that TSC1/2 
knockdown induced only very mild feedback inhibition from S6K to the insulin 
pathway in TSCsi293 cells and obtained results, which indicate that co-activators like 
PI3K and ERK1/2 potentially fine tune signal transduction downstream of mTORC2, 
creating adequate responses to a variable set of extracellular stimuli. 
 
 
Figure IV-11. 
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Figure IV-11. Comparison of TSCsi293 cells, stimulated with either amino acids, 
serum, or insulin or a combination of those. 
Phosphorylation of Paxillin Tyr118 (pY118), Akt/PKB Ser473 (pS473), Akt/PKB 
Thr308 (pT308), S6K Thr389 (T389) and ERK1/2 Thr202/Tyr204 (pT202/Y204) was 
detected 30 minutes after stimulation with either amino acids and serum, serum 
alone, amino acids and insulin, or insulin alone.  Western analysis of TSCsi293 cells 
either induced for TSC1/2 knockdown or not.  The cells were grown for 30 minutes in 
D-PBS+ supplemented as indicated before lysis. 
 
 
IV.1.12  Phosphorylation of the mTORC2 readouts Paxillin Tyr118 and Akt/PKB 
Ser473 is mTORC1-independent. 
 
We expected that knockdown of TSC1/2 would activate mTORC1 in TSCsi293 cells.  
To determine if hyperactivation of mTORC1 affected our readouts for mTORC2 
activity, we inhibited mTORC1 specifically with rapamycin and examined 
phosphorylation of Paxillin Tyr118 or Akt/PKB Ser473 in tetracycline treated and 
untreated TSCsi293 cells upon serum stimulation.  Rapamycin did not prevent 
phosphorylation of Paxillin Tyr118 or PKB Ser473 upon serum stimulation, 
independently of TSC1/2 knockdown, while loss of S6K Thr389 phosphorylation 
confirmed mTORC1 inhibition by rapamycin (Figure IV-12).  This result showed that 
mTORC1 did not affect Paxillin Tyr118 phosphorylation upon knockdown of TSC1/2 
or stimulation with serum. 
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Figure IV-12. 
 
 
 
 
Figure IV-12. mTORC1 inhibition by rapamycin does not block phosphorylation of 
mTORC2 readouts. 
Phosphorylation of Paxillin Tyr118 (pY118), Akt/PKB Ser473 (pS473) and S6K 
Thr389 (pT389) was detected 30 minutes after stimulation with serum.  Western 
analysis of TSCsi293 cells either induced for TSC1/2 knockdown or not.  We pre-
incubated the cells with rapamycin at indicated concentrations for 30 minutes, using 
DMSO (1:2000) as vehicle.  The cells were then grown for 30 minutes in D-PBS+ 
supplemented with 10 % serum and rapamycin at the indicated concentrations before 
lysis. 
 
 
IV.1.13  Also in serum stimulated cells, mTORC2 mediates increased 
phosphorylation of Paxillin Tyr118 resulting from TSC1/2 knockdown. 
 
To determine if mTORC2 also mediates increased phosphorylation of Paxillin Tyr118 
due to TSC1/2 knockdown in serum stimulated TSCsi293 cells, we inhibited 
mTORC2 in tetracycline treated TSCsi293 cells, stimulated them with serum and 
examined phosphorylation of Paxillin and PKB.  We inhibited mTORC2 specifically by 
co-siRNA against rictor using a pSuper-based plasmid.  Knockdown of rictor was 
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confirmed by loss of rictor protein and by loss of Akt/PKB Ser473 phosphorylation.  
Rictor co-siRNA prevented the increase in Paxillin Tyr118 phosphorylation, resulting 
from TSC1/2 knockdown also during serum stimulation (Figure IV-13).  Thus, 
mTORC2 activity is required for serum stimulated Paxillin Tyr118 phosphorylation in 
TSC1/2 knockdown cells. 
 
 
Figure IV-13. 
 
 
 
Figure IV-13. mTORC2 mediates the effects of TSC1/2 knockdown also upon serum 
stimulation. 
Also upon serum stimulation, co-knockdown of mTORC2 (rictor co-siRNA) prevents 
increased Paxillin Tyr118 phosphorylation (Paxillin-pY118) due to TSC1/2 
knockdown and leads to loss of PKB Ser473 phosphorylation (PKB-pS473).  Western 
analysis of TSCsi293 cells (+/- tetracycline induced TSC1/2 siRNA), transiently 
expressing the indicated co-siRNA.  The cells were grown for 30 minutes in PBS+ 
supplemented with 10 % serum before lysis.  
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IV.1.14  Activities of mTOR and ERK1/2 are both required for efficient Paxillin 
Tyr118 phosphorylation upon serum stimulation. 
 
To further determine if ERK1/2 signaling is required for efficient mTORC2-dependent 
phosphorylation of Paxillin Tyr118 upon serum stimulation, we pharmacologically 
inhibited either ERK1/2 or mTORC2 in TSCsi293 cells before stimulation. For 
inhibition of ERK1/2 we treated the cells with U0126 and for mTORC2 inhibition we 
treated the cells with LY294002 at an mTOR inhibiting concentration. Inhibition of 
either ERK1/2 or mTORC2 prevented serum stimulated phosphorylation of Paxillin 
Tyr118 (Figure IV-14).  
The MEK1/2-specific inhibitor U0126 efficiently blocked ERK1/2 Thr202/Tyr204 
phosphorylation, and thus ERK1/2 activity, but not mTORC2 activity as mTORC2-
dependent phosphorylation of PKB Ser473 did not change. LY294002 blocked 
mTORC2-dependent phosphorylation of Akt/PKB Ser473 only at mTOR inhibiting 
concentrations but not ERK1/2 phosphorylation. These results indicate that serum-
induced phosphorylation of Paxillin Tyr118 requires activation of ERK1/2 in addition 
to activation of mTORC2. The finding that inhibition of ERK1/2 did not block 
mTORC2-dependent activation of Akt/PKB and that inhibition of mTORC2 did not 
block ERK1/2 activation additionally showed that ERK1/2 and mTORC2 rather signal 
in parallel and are not immediately upstream of each other. Thus, the difference 
between stimulation with serum compared to insulin towards the mTORC2-
dependent readouts Paxillin and PKB is likely to rely on differentially activated co-
factors by either serum or insulin.  
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Figure IV-14. 
 
 
 
Figure IV-14. Inhibition of either mTOR or ERK1/2 blocks Paxillin Tyr118 
phosphorylation upon serum stimulation. 
Phosphorylation of Paxillin Tyr118 (pY118), Akt/PKB Ser473 (pS473), S6K Thr389 
(pT389) and ERK1/2 Thr202/Tyr204 (pT202/Y204) was detected 30 minutes after 
stimulation with serum.  Western analysis of TSCsi293 cells either induced for 
TSC1/2 knockdown or not.  We pre-incubated the cells for 30 minutes with LY294002 
at PI3K inhibiting concentrations (2 µM) or at mTOR inhibiting concentrations (30 
µM), or with U0126 at MEK1/2 inhibiting concentrations (25 µM), using DMSO 
(1:2000) as vehicle.  The cells were then grown for 30 minutes in D-PBS+ 
supplemented with 10 % serum and the indicated inhibitors before lysis. 
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IV.1.15  Re-expression of TSC1/2 reduced Paxillin Tyr118 phosphorylation upon 
TSC1/2 knockdown. 
 
To obtain further evidence that the increase in Paxillin Tyr118 phosphorylation upon 
TSC1/2 knockdown in TSCsi293 cells resulted from reduced levels of TSC1/2 
proteins, we transiently re-introduced knockdown resistant versions of TSC1 and 
TSC2 into TSCsi293 cells while inducing TSC1/2 knockdown. Re-introduction of 
TSC1/2 in TSCsi293 cells partially reduced phosphorylation of Paxillin Tyr118 upon 
TSC1/2 knockdown (Figure IV-15). This provided a further control that the increased 
Paxillin Tyr118 phosphorylation upon TSC1/2 knockdown resulted from the reduction 
of TSC1/2 protein levels. 
 
 
Figure IV-15. 
 
 
 
 
Figure IV-15.  TSC1/2 re-expression in tetracycline treated TSCsi293 cells reduced 
phosphorylation of Paxillin Tyr118 upon serum stimulation.  
Phosphorylation of Paxillin Tyr118 (pY118) was detected 30 minutes after serum 
stimulation.  Western analysis of TSCsi293 cells either induced for TSC1/2 siRNA or 
not.  The cells were transfected with either GFP or TSC1 and TSC2, each harbouring 
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three silent mutations within their target regions for siRNA mediated knockdown.  The 
cells were grown for 30 minutes in D-PBS+ supplemented with 10 % serum before 
lysis. 
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IV.2 Discussion 
 
 
We found that amino acids stimulate the mTORC1 readout S6K1 Thr389 
phosphorylation in a transient manner (Figure IV-9).  The decline of S6K Thr389 
phosphorylation after a short transient peak at about 30 minutes post stimulation 
suggests that a feedback mechanism exists, which inhibits prolonged hyperactivation 
of S6K1.  It is possible that the reduction in S6K Thr389 phosphorylation following a 
peak after amino acid stimulation represents reduced mTORC1 activity based on the 
observation that mTORC1-dependent 4E-BP1 phosphorylation follows the same 
pattern of S6K Thr389 phosphorylation (Figure IV-9).  To further understand if 
mTORC1 activity is also reduced, it would be interesting to see if Rheb binding to 
mTORC1 correlates over time with the phosphorylation intensity of the mTORC1 
readouts as Rheb binding to mTORC1 has been found to increase after amino acid 
stimulation.  It would also be of interest to determine mTOR phosphorylation on Ser 
2448 in mTORC1 by S6K1 in this experiment. Presumably, S6K1 activation upon 
amino acid stimulation induces mTOR Ser2448 phosphorylation in TSCsi293 cells 
(Holz and Blenis, 2005).  The physiological function of mTOR phosphorylation on 
Ser2448 is unknown and therefore the speculation is justified that mTOR Ser2448 
phosphorylation in mTORC1 by S6K1 might represent a negative feedback 
mechanism towards amino acid stimulation.  Our observation that TSCsi293 cells in 
which we knocked down TSC1/2 still do respond to amino acid stimulation like 
normal cells (Figure IV-9) provides additional evidence for the concept that amino 
acids do not primarily stimulate mTORC1 via inhibition of TSC1-TSC2.  
 
Like stimulation with amino acids induced a transient phosphorylation pattern, 
serum stimulated phosphorylation of the mTORC2 readout Paxillin Tyr118 also in a 
transient manner, suggesting that a negative feedback mechanism may exist to limit 
the effects of serum stimulation (Figure IV-4).  This limitation of the response to 
serum stimulation may have several reasons.  As serum contains a non-defined mix 
of growth factors it is possible that either feedback mechanisms towards growth 
factor receptors or inhibiting growth factors present in the serum account for this 
limitation.  However, the broad spectrum of possible mechanisms, which could 
account for such a feedback control, makes it difficult to speculate about the nature of 
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the transient Paxillin Tyr118 phosphorylation upon serum stimulation.  We also found 
that serum stimulates phosphorylation of Paxillin Tyr118 and Akt/PKB Ser473 in a 
way that is different to insulin stimulation in our system (see IV.11), which illustrates 
the  capability of cells to fine tune their signaling response to distinct extracellular 
stimuli.  Serum efficiently stimulates Akt/PKB phosphorylation on Ser473 only after 
the cells were pre-starved for serum (Figures IV-4, IV-6 and IV-11), while Paxillin 
Tyr118 phosphorylation is found strongly induced upon serum stimulation (Figure IV-
4 and IV-11).  On the other hand, insulin induces Ser473 phosphorylation in Akt/PKB 
even without prior serum starvation (Figure IV-7), while insulin does not efficiently 
induce Paxillin Tyr118 phosphorylation without serum pre-starvation (Figures IV-7, 
IV-8 and IV-11).  We did not measure the difference between the two stimuli towards 
PI3K activation but presumably, PI3K activity correlates with Akt/PKB Ser473 
phosphorylation in our system.   
 
We observed another important difference between insulin and serum 
stimulation when we measured ERK1/2 activation. ERK1/2 activation is much 
stronger induced by serum stimulation compared to stimulation with insulin (Figure 
IV-11).  Initial experiments, using siRNA to inhibit mTORC2 (Figure IV-13) and 
pharmacological inhibitiors for mTOR and ERK1/2 (Figure IV-14) provided 
encouraging results that the efficiency of mTORC2-dependent phosphorylation of 
Paxillin Tyr118 arising from serum stimulation might be co-regulated by ERK1/2 
activation.  In addition to the pharmacological inhibition of ERK1/2 and mTOR during 
serum starvation (Figure IV-13) it will be necessary to more specifically inhibit 
ERK1/2 and mTORC2 by siRNA mediated knockdown in combination with serum 
stimulation to validate our results.  If ERK1/2 indeed turns out to co-regulate the 
mTORC2 readout Paxillin Tyr118 phosphorylation, this would represent the second 
downstream readout of mTORC2 that is tightly co-regulated next to co-regulated 
mTORC2-dependent Akt/PKB Ser473 phosphorylation by PI3K.  Such tight 
regulatory mechanism indicate that, if unrestricted, mTORC2 signaling towards the 
actin cytoskeleton and possibly also towards other readouts has a high potential to 
promote life threatening steps in disease such as metastasis in cancer.  To further 
determine the role of TSC1-TSC2 in upstream regulation of mTORC2, it will be 
interesting to test different TSC2 mutant constructs that cannot be inactivated by 
ERK1/2 (Ma et al., 2005a).   
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As we could show that mTORC2 is inhibited by TSC1-TSC2, it will be interesting to 
understand the impact of other stimuli, that are known to regulate mTORC1 via 
regulation of TSC1-TSC2, towards mTORC2 such as energy and oxygen.  Because 
signal transduction from TSC1-TSC2 towards mTORC2 is apparently different from 
transduction towards mTORC1, we cannot predict how energy or hypoxia affect 
mTORC2 activity.  The TSCsi293 cell line is a suitable system to address these 
questions and with more information about the upstream signals that regulate 
mTORC2 we could widen our understanding of the mTOR signaling network. 
 
We cannot explain the mechanism by which TSC1-TSC2 inhibits mTORC2 as 
we find that TSC1-TSC2 regulates mTORC2 via an unknown mechanism that is 
different from mTORC1 regulation by TSC1-TSC2.  It will be important to determine if 
mTORC2 inhibition involves so far unknown proteins or if there is a more direct 
mechanism that links TSC1-TSC2 with mTORC2 regulation.   It will also be important 
to determine the signaling pathway by which mTORC2 regulates actin organization 
and presumably the adhesion and migration behaviour of cells to further understand 
if and how mTORC2 might affect processes in development that rely on tightly 
regulated cell migration or contribute to diseases that arise from aberrant migration.  
 
Because TORC2 regulates transcription in yeast and mTORC2 apparently 
regulates the FoxO transcription factors (see I.4.2 and I.4.7), it will be also interesting 
to investigate if TSC1-TSC2 deficiency induces mTORC2-dependent gene 
transcription.  We believe that the TSCsi293 cell line is also a suitable system to 
study mTORC2-dependent effects on transcription.  In comparison to tsc1-/- and  
tsc2-/-  knockout cells, induced siRNA-mediated knockdown inhibits TSC1-TSC2 
signaling only over a short time period, limiting cellular adaptation and resulting in 
demonstrated hyperactivation of mTORC2 signaling (Figures III-2 and III-3). This 
system has additionally the advantage that we already established an efficient 
epistatic siRNA approach to co-inhibit mTORC2 together with TSC1-TSC2.  
Increasing knowledge about the signal transduction controlled by mTORC2 promises 
to provide us with new insights into the biology behind diseases such as tuberous 
sclerosis complex, lympangioleiomyomathosis and cancer that result from 
overgrowing and aberrantly migrating cells. 
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